

# **Dossier zur Nutzenbewertung gemäß § 35a SGB V**

*Zolbetuximab (VYLOY™)*

**Astellas Pharma GmbH**

## **Modul 4 A, Anhang 4-G3**

*Erstlinienbehandlung von erwachsenen Patienten mit  
lokal fortgeschrittenem inoperablem oder metastasiertem  
HER2-negativem Adenokarzinom des Magens oder des GEJ,  
deren Tumore Claudin18.2 positiv sind*

*Metaanalyse aus den beiden Studien GLOW und FAST*

*GLOW: Finaler Datenschnitt vom 12.01.2024*

*FAST: Finaler Datenschnitt vom 31.01.2019*

Stand: 30.10.2024

# Inhaltsverzeichnis

<b>Anhang 4-G3 Metaanalyse aus den beiden Studien GLOW und FAST .....</b>	<b>2</b>
<b>Anhang 4-G3 Baseline Charakteristika .....</b>	<b>2</b>
<b>Anhang 4-G3 Gesamtüberleben und Progressionsfreies Überleben .....</b>	<b>6</b>
Anhang 4-G3 Gesamtüberleben .....	7
Anhang 4-G3 Progressionsfreies Überleben .....	21
<b>Anhang 4-G3 Patientenberichtete Endpunkte.....</b>	<b>47</b>
Anhang 4-G3 Symptomatik und Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30 .....	48
<b>Anhang 4-G3 Sicherheit.....</b>	<b>123</b>
Anhang 4-G3 Unerwünschte Ereignisse .....	124
Anhang 4-G3 Schwere unerwünschte Ereignisse .....	129
Anhang 4-G3 Schwerwiegende unerwünschte Ereignisse .....	134
Anhang 4-G3 Abbruch der Studienmedikation aufgrund unerwünschter Ereignisse .....	139
Anhang 4-G3 Unerwünschte Ereignisse - SOC und PT.....	144
Anhang 4-G3 Schwerwiegende unerwünschte Ereignisse - SOC und PT .....	309
Anhang 4-G3 Schwere unerwünschte Ereignisse - SOC und PT .....	341
Anhang 4-G3 Abbruch der Studienmedikation aufgrund unerwünschter Ereignisse - SOC und PT.....	396
Anhang 4-G3 Unerwünschte Ereignisse von besonderem Interesse .....	400

## **Baselinecharakteristika**

Medizinischer Nutzen, medizinischer Zusatznutzen, Patientengruppen mit therap. bedeutsamem Zusatznutzen

Table A.2MA.1.1001.1: Summary of Baseline Demographics - Full Analysis Set

Parameter and Category/Statistic	Zolbetuximab (N=310)	Placebo (N=311)
Sex		
Male	191 ( 61.6%)	193 ( 62.1%)
Female	119 ( 38.4%)	118 ( 37.9%)
Unknown	0	0
Age (years)		
n	310	311
Mean (SD)	58.34 ( 11.79)	56.48 ( 12.62)
Median	60.0	58.0
Range	22.0 - 82.0	21.0 - 83.0
Age (years)		
>=18 to <=64	210 ( 67.7%)	220 ( 70.7%)
>=65 to <85	100 ( 32.3%)	91 ( 29.3%)
Age Group 1 (years)		
<=65	220 ( 71.0%)	228 ( 73.3%)
>65	90 ( 29.0%)	83 ( 26.7%)
Age Group 2 (years)		
<=75	297 ( 95.8%)	297 ( 95.5%)
>75	13 ( 4.2%)	14 ( 4.5%)
Race		
White	146 ( 47.4%)	145 ( 47.4%)
Black or African American	0	0
Asian	158 ( 51.3%)	158 ( 51.6%)
American Indian or Alaska Native	0	0
Native Hawaiian or Other Pacific Islander	0	0
Other	4 ( 1.3%)	3 ( 1.0%)
Missing	2	5

Abbreviations: BMI=body mass index; BSA=body surface area; ECOG=eastern cooperative oncology group; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.  
 ASTELLAS final Data Cuts

Table A.2MA.1.1001.1: Summary of Baseline Demographics - Full Analysis Set

Parameter and Category/Statistic	Zolbetuximab (N=310)	Placebo (N=311)
Height (cm)		
n	309	308
Mean (SD)	165.56 ( 9.21)	165.68 ( 8.55)
Median	165.4	165.5
Range	145.0 - 196.0	141.5 - 189.0
Weight (kg)		
n	309	308
Mean (SD)	63.08 ( 14.27)	60.89 ( 12.64)
Median	61.0	60.0
Range	35.5 - 113.0	29.1 - 102.0
BMI (kg/m <sup>2</sup> )		
<18.5	41 ( 13.3%)	46 ( 14.9%)
>=18.5 to <25	175 ( 56.6%)	196 ( 63.6%)
>=25 to <30	73 ( 23.6%)	60 ( 19.5%)
>=30	20 ( 6.5%)	6 ( 1.9%)
Missing	1	3
BSA (m <sup>2</sup> )		
n	309	308
Mean (SD)	1.69 ( 0.21)	1.66 ( 0.20)
Median	1.7	1.7
Range	1.2 - 2.5	1.1 - 2.3
BSA (m <sup>2</sup> )		
<1.7	147 ( 47.6%)	166 ( 53.9%)
>=1.7	162 ( 52.4%)	142 ( 46.1%)
Missing	1	3
Baseline ECOG Status		

Abbreviations: BMI=body mass index; BSA=body surface area; ECOG=eastern cooperative oncology group; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.  
ASTELLAS final Data Cuts

Table A.2MA.1.1001.1: Summary of Baseline Demographics - Full Analysis Set

Parameter and Category/Statistic	Zolbetuximab (N=310)	Placebo (N=311)
0	128 ( 41.4%)	124 ( 40.3%)
>=1	181 ( 58.6%)	184 ( 59.7%)
Missing	1	3
Region		
Asia	157 ( 50.6%)	158 ( 50.8%)
Non-Asia	153 ( 49.4%)	153 ( 49.2%)
Number of Organs with Metastatic Sites		
0-2	207 ( 66.8%)	206 ( 66.2%)
>=3	103 ( 33.2%)	105 ( 33.8%)
Prior Gastrectomy		
Yes	88 ( 28.4%)	91 ( 29.3%)
No	222 ( 71.6%)	220 ( 70.7%)

Abbreviations: BMI=body mass index; BSA=body surface area; ECOG=eastern cooperative oncology group; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.  
ASTELLAS final Data Cuts

## **Gesamtüberleben und Progressionsfreies Überleben**

**A-MA.3.1002.1.1: Forest Plot for Hazard Ratio of Overall Survival - Full Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	180 / 254	207 / 253	80.0	0.763 [0.622, 0.936]
GM03 – FAST	45 / 56	54 / 58	20.0	0.493 [0.328, 0.742]
<b>Total</b>	<b>225 / 310</b>	<b>261 / 311</b>	<b>100</b>	<b>0.699 [0.582, 0.839]</b>
Heterogeneity	Q = 3.52 (df = 1)	p = 0.0607	I <sup>2</sup> = 71.6%	p(Effect) = 0.0001






Table MA.1002.1.1: Summary of Overall Survival - Full Analysis Set


	Zolbetuximab + chemotherapy (N=310)	(Placebo) + chemotherapy (N=311)	Zolbetuximab + chemotherapy vs. (Placebo) + chemotherapy
Number of patients at risk	310 (100.0%)	311 (100.0%)	
Number of patients with events	225 ( 72.6%)	261 ( 83.9%)	
Number of patients censored	85 ( 27.4%)	50 ( 16.1%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	82.6 [ 77.8, 86.5]	76.1 [ 70.8, 80.5]	6.6 [ 0.1, 13.1], p=0.0471
Month 12	57.7 [ 51.8, 63.2]	46.8 [ 40.9, 52.4]	11.0 [ 2.9, 19.1], p=0.0079
Month 18	40.8 [ 35.1, 46.5]	26.1 [ 21.1, 31.3]	14.7 [ 7.0, 22.4], p=0.0002
Month 24	30.3 [ 24.9, 35.7]	16.6 [ 12.5, 21.2]	13.6 [ 6.7, 20.6], p=0.0001
Month 30	23.2 [ 18.2, 28.6]	12.0 [ 8.4, 16.2]	11.2 [ 4.6, 17.7], p=0.0008
Month 36	17.6 [ 12.9, 22.9]	8.2 [ 5.1, 12.2]	9.4 [ 3.2, 15.5], p=0.0028
Month 42	15.8 [ 11.1, 21.2]	6.8 [ 3.6, 11.3]	8.9 [ 2.6, 15.3], p=0.0060
Month 48	14.3 [ 9.5, 20.1]	6.8 [ 3.6, 11.3]	7.5 [ 0.9, 14.1], p=0.0254
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	14.4 [ 12.5, 16.5]	11.1 [ 9.8, 12.6]	

Abbreviations: CI=confidence interval; N=number of patients; NC=not calculated.


(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.

ASTELLAS Data Cutoff Date: 12JAN2024 (GLOW) & 31JAN2019 (FAST)


**A-MA.3.1002.1.2: Forest Plot for Hazard Ratio of Overall Survival by Age Group 1 - Full Analysis Set**




**A-MA.3.1002.1.3: Forest Plot for Hazard Ratio of Overall Survival by Age Group 2 - Full Analysis Set**




**A-MA.3.1002.1.4: Forest Plot for Hazard Ratio of Overall Survival by Sex - Full Analysis Set**




**A-MA.3.1002.1.5: Forest Plot for Hazard Ratio of Overall Survival by Race - Full Analysis Set**




### A-MA.3.1002.1.6: Forest Plot for Hazard Ratio of Overall Survival by Tobacco History - Full Analysis Set



**A-MA.3.1002.1.7: Forest Plot for Hazard Ratio of Overall Survival by Region - Full Analysis Set**




**A-MA.3.1002.1.8: Forest Plot for Hazard Ratio of Overall Survival by Number of Organs with Metastatic Sites - Full Analysis Set**







**A-MA.3.1002.1.9: Forest Plot for Hazard Ratio of Overall Survival by Prior Gastrectomy (total or partial) - Full Analysis Set**




### A-MA.3.1002.1.10: Forest Plot for Hazard Ratio of Overall Survival by Histology (Tumor Type) - Full Analysis Set




**A-MA.3.1002.1.11: Forest Plot for Hazard Ratio of Overall Survival by Tumor Location 1 - Full Analysis Set**



### A-MA.3.1002.1.12: Forest Plot for Hazard Ratio of Overall Survival by Tumor Location 2 - Full Analysis Set




### A-MA.3.1002.1.13: Forest Plot for Hazard Ratio of Overall Survival by Tumor Location 3 - Full Analysis Set




**A-MA.3.1002.2.1: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	153 / 254	182 / 253	84.3	0.689 [0.552, 0.860]
GM03 – FAST	31 / 56	44 / 58	15.7	0.387 [0.231, 0.646]
<b>Total</b>	<b>184 / 310</b>	<b>226 / 311</b>	<b>100</b>	<b>0.629 [0.513, 0.772]</b>
Heterogeneity	Q = 4.08 (df = 1)	p = 0.0435	I <sup>2</sup> = 75.5%	p(Effect) < 0.0001



### A-MA.3.1002.2.2: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Age Group 1 - Full Analysis Set




### A-MA.3.1002.2.3: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Age Group 2 - Full Analysis Set







### A-MA.3.1002.2.4: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Sex - Full Analysis Set




### A-MA.3.1002.2.5: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Race - Full Analysis Set




**A-MA.3.1002.2.6: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Tobacco History - Full Analysis Set**




**A-MA.3.1002.2.7: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Region - Full Analysis Set**




### A-MA.3.1002.2.8: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Number of Organs with Metastatic Sites - Full Analysis Set




**A-MA.3.1002.2.9: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Prior Gastrectomy (total or partial) - Full Analysis Set**



**A-MA.3.1002.2.10: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Histology (Tumor Type) - Full Analysis Set**




### A-MA.3.1002.2.11: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Tumor Location 1 - Full Analysis Set






### A-MA.3.1002.2.12: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Tumor Location 2 - Full Analysis Set




**A-MA.3.1002.2.13: Forest Plot for Hazard Ratio of Progression-Free Survival (IRC) by Tumor Location 3 - Full Analysis Set**




**A-MA.3.1002.3.1: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	173 / 254	210 / 253	83.1	0.671 [0.544, 0.828]
GM03 – FAST	39 / 56	45 / 58	16.9	0.470 [0.295, 0.749]
<b>Total</b>	<b>212 / 310</b>	<b>255 / 311</b>	<b>100</b>	<b>0.632 [0.522, 0.765]</b>
Heterogeneity	Q = 1.86 (df = 1)	p = 0.1721	I <sup>2</sup> = 46.4%	p(Effect) < 0.0001




**A-MA.3.1002.3.2: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Age Group 1 - Full Analysis Set**




### A-MA.3.1002.3.3: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Age Group 2 - Full Analysis Set




### A-MA.3.1002.3.4: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Sex - Full Analysis Set



### A-MA.3.1002.3.5: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Race - Full Analysis Set




**A-MA.3.1002.3.6: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Tobacco History - Full Analysis Set**







**A-MA.3.1002.3.7: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Region - Full Analysis Set**




### A-MA.3.1002.3.8: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Number of Organs with Metastatic Sites - Full Analysis Set




### A-MA.3.1002.3.9: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Prior Gastrectomy (total or partial) - Full Analysis Set




**A-MA.3.1002.3.10: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Histology (Tumor Type) - Full Analysis Set**




### A-MA.3.1002.3.11: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Tumor Location 1 - Full Analysis Set



### A-MA.3.1002.3.12: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Tumor Location 2 - Full Analysis Set



**A-MA.3.1002.3.13: Forest Plot for Hazard Ratio of Progression-Free Survival (INV) by Tumor Location 3 - Full Analysis Set**




## **Patientenberichtete Endpunkte**




**A-MA.1.3004.3.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Global Health Status (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	132 / 254	147 / 253	86.9	0.969 [0.761, 1.234]
GM03 – FAST	19 / 56	27 / 58	13.1	0.400 [0.215, 0.745]
<b>Total</b>	<b>151 / 310</b>	<b>174 / 311</b>	<b>100</b>	<b>0.863 [0.689, 1.081]</b>
Heterogeneity	Q = 6.77 (df = 1)	p = 0.0093	I <sup>2</sup> = 85.2%	p(Effect) = 0.1985




**A-MA.1.3004.3.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Global Health Status by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.3.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Global Health Status by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.3.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Global Health Status by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.3.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Global Health Status by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.4.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Physical Functioning (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	140 / 254	142 / 253	85.0	1.100 [0.867, 1.396]
GM03 – FAST	24 / 56	27 / 58	15.0	0.669 [0.380, 1.179]
<b>Total</b>	<b>164 / 310</b>	<b>169 / 311</b>	<b>100</b>	<b>1.021 [0.820, 1.271]</b>
Heterogeneity	Q = 2.52 (df = 1)	p = 0.1125	I <sup>2</sup> = 60.3%	p(Effect) = 0.8545



**A-MA.1.3004.4.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Physical Functioning by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.4.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Physical Functioning by Sex (MID=10) - Full Analysis Set**






**A-MA.1.3004.4.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Physical Functioning by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.4.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Physical Functioning by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.5.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Role Functioning (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	146 / 254	156 / 253	86.4	0.884 [0.703, 1.112]
GM03 – FAST	23 / 56	25 / 58	13.6	0.689 [0.387, 1.229]
<b>Total</b>	<b>169 / 310</b>	<b>181 / 311</b>	<b>100</b>	<b>0.855 [0.691, 1.057]</b>
Heterogeneity	Q = 0.62 (df = 1)	p = 0.4320	I <sup>2</sup> = 0.0%	p(Effect) = 0.1482




**A-MA.1.3004.5.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Role Functioning by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.5.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Role Functioning by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.5.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Role Functioning by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.5.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Role Functioning by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.6.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Emotional Functioning (MID=10) - Full Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	118 / 254	114 / 253	85.0	1.073 [0.826, 1.395]
GM03 – FAST	22 / 56	21 / 58	15.0	0.813 [0.435, 1.517]
<b>Total</b>	<b>140 / 310</b>	<b>135 / 311</b>	<b>100</b>	<b>1.029 [0.808, 1.311]</b>
Heterogeneity	Q = 0.64 (df = 1)	p = 0.4220	I <sup>2</sup> = 0.0%	p(Effect) = 0.8145







**A-MA.1.3004.6.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Emotional Functioning by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.6.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Emotional Functioning by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.6.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Emotional Functioning by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.6.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Emotional Functioning by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.7.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Cognitive Functioning (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	135 / 254	130 / 253	84.5	1.136 [0.890, 1.450]
GM03 – FAST	25 / 56	24 / 58	15.5	0.922 [0.522, 1.629]
<b>Total</b>	<b>160 / 310</b>	<b>154 / 311</b>	<b>100</b>	<b>1.100 [0.879, 1.376]</b>
Heterogeneity	Q = 0.44 (df = 1)	p = 0.5088	I <sup>2</sup> = 0.0%	p(Effect) = 0.4060




**A-MA.1.3004.7.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Cognitive Functioning by Age Group 1 (MID=10) - Full Analysis Set**



**A-MA.1.3004.7.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Cognitive Functioning by Sex (MID=10) - Full Analysis Set**




**A-MA.1.3004.7.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Cognitive Functioning by Region (MID=10) - Full Analysis Set**






**A-MA.1.3004.7.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Cognitive Functioning by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.8.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Social Functioning (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	133 / 254	139 / 253	85.0	0.970 [0.762, 1.234]
GM03 – FAST	25 / 56	25 / 58	15.0	0.885 [0.498, 1.572]
<b>Total</b>	<b>158 / 310</b>	<b>164 / 311</b>	<b>100</b>	<b>0.957 [0.766, 1.195]</b>
Heterogeneity	Q = 0.08 (df = 1)	p = 0.7730	I <sup>2</sup> = 0.0%	p(Effect) = 0.6969




**A-MA.1.3004.8.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Social Functioning by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.8.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Social Functioning by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.8.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Social Functioning by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.8.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Social Functioning by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.9.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Fatigue (MID=10) - Full Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	169 / 254	171 / 253	85.6	1.076 [0.867, 1.337]
GM03 – FAST	27 / 56	31 / 58	14.4	0.771 [0.454, 1.308]
<b>Total</b>	<b>196 / 310</b>	<b>202 / 311</b>	<b>100</b>	<b>1.026 [0.839, 1.253]</b>
Heterogeneity	Q = 1.31 (df = 1)	p = 0.2531	I <sup>2</sup> = 23.4%	p(Effect) = 0.8037




**A-MA.1.3004.9.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Fatigue by Age Group 1 (MID=10) - Full Analysis Set**







**A-MA.1.3004.9.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Fatigue by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.9.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Fatigue by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.9.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Fatigue by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.10.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Nausea and Vomiting (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	164 / 254	144 / 253	85.8	1.575 [1.248, 1.986]
GM03 – FAST	25 / 56	26 / 58	14.2	0.947 [0.535, 1.676]
<b>Total</b>	<b>189 / 310</b>	<b>170 / 311</b>	<b>100</b>	<b>1.465 [1.182, 1.817]</b>
Heterogeneity	Q = 2.62 (df = 1)	p = 0.1058	I <sup>2</sup> = 61.8%	p(Effect) = 0.0005




**A-MA.1.3004.10.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Nausea and Vomiting by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.10.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Nausea and Vomiting by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.10.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Nausea and Vomiting by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.10.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Nausea and Vomiting by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**






**A-MA.1.3004.11.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Pain (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	136 / 254	149 / 253	86.4	0.948 [0.746, 1.204]
GM03 – FAST	23 / 56	22 / 58	13.6	0.816 [0.447, 1.492]
<b>Total</b>	<b>159 / 310</b>	<b>171 / 311</b>	<b>100</b>	<b>0.929 [0.744, 1.160]</b>
Heterogeneity	Q = 0.21 (df = 1)	p = 0.6504	I <sup>2</sup> = 0.0%	p(Effect) = 0.5154




**A-MA.1.3004.11.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Pain by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.11.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Pain by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.11.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Pain by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.11.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Pain by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.12.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Dyspnoea (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	97 / 254	108 / 253	85.5	0.906 [0.686, 1.197]
GM03 – FAST	18 / 56	17 / 58	14.5	0.775 [0.394, 1.524]
<b>Total</b>	<b>115 / 310</b>	<b>125 / 311</b>	<b>100</b>	<b>0.886 [0.685, 1.146]</b>
Heterogeneity	Q = 0.18 (df = 1)	p = 0.6756	I <sup>2</sup> = 0.0%	p(Effect) = 0.3555



**A-MA.1.3004.12.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Dyspnoea by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.12.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Dyspnoea by Sex (MID=10) - Full Analysis Set**






**A-MA.1.3004.12.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Dyspnoea by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.12.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Dyspnoea by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.13.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Insomnia (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	122 / 254	121 / 253	89.3	1.015 [0.786, 1.310]
GM03 – FAST	18 / 56	13 / 58	10.7	0.968 [0.463, 2.025]
<b>Total</b>	<b>140 / 310</b>	<b>134 / 311</b>	<b>100</b>	<b>1.010 [0.793, 1.286]</b>
Heterogeneity	Q = 0.01 (df = 1)	p = 0.9053	I <sup>2</sup> = 0.0%	p(Effect) = 0.9365




**A-MA.1.3004.13.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Insomnia by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.13.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Insomnia by Sex (MID=10) - Full Analysis Set**



### A-MA.1.3004.13.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Insomnia by Region (MID=10) - Full Analysis Set




**A-MA.1.3004.13.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Insomnia by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.14.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Appetite Loss (MID=10) - Full Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	143 / 254	137 / 253	86.5	1.251 [0.986, 1.586]
GM03 – FAST	21 / 56	25 / 58	13.5	0.746 [0.408, 1.362]
<b>Total</b>	<b>164 / 310</b>	<b>162 / 311</b>	<b>100</b>	<b>1.167 [0.935, 1.456]</b>
Heterogeneity	Q = 2.45 (df = 1)	p = 0.1178	I <sup>2</sup> = 59.1%	p(Effect) = 0.1711






**A-MA.1.3004.14.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Appetite Loss by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.14.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Appetite Loss by Sex (MID=10) - Full Analysis Set**


Subgroup Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
<b>Male</b>				
302 – GLOW	91 / 159	88 / 156	55.7	1.111 [0.829, 1.490]
GM03 – FAST	11 / 32	17 / 37	7.7	0.573 [0.260, 1.264]
<b>Total</b>	<b>102 / 191</b>	<b>105 / 193</b>	<b>63.4</b>	<b>1.026 [0.779, 1.350]</b>
Heterogeneity	Q = 2.37 (df = 1)	p = 0.1238	I <sup>2</sup> = 57.8%	p(Effect) = 0.8572
<b>Female</b>				
302 – GLOW	52 / 95	49 / 97	31.1	1.383 [0.934, 2.048]
GM03 – FAST	10 / 24	8 / 21	5.5	1.061 [0.417, 2.697]
<b>Total</b>	<b>62 / 119</b>	<b>57 / 118</b>	<b>36.6</b>	<b>1.329 [0.925, 1.908]</b>
Heterogeneity	Q = 0.26 (df = 1)	p = 0.6079	I <sup>2</sup> = 0.0%	p(Effect) = 0.1234
<b>Heterogeneity</b>	<b>Q = 1.25 (df = 1)</b>	<b>p = 0.2636</b>	<b>I<sup>2</sup> = 22.7%</b>	



**A-MA.1.3004.14.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Appetite Loss by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.14.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Appetite Loss by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.15.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Constipation (MID=10) - Full Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	93 / 254	102 / 253	86.6	0.956 [0.719, 1.273]
GM03 – FAST	16 / 56	15 / 58	13.4	0.793 [0.384, 1.638]
<b>Total</b>	<b>109 / 310</b>	<b>117 / 311</b>	<b>100</b>	<b>0.932 [0.715, 1.216]</b>
Heterogeneity	Q = 0.22 (df = 1)	p = 0.6383	I <sup>2</sup> = 0.0%	p(Effect) = 0.6052




**A-MA.1.3004.15.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Constipation by Age Group 1 (MID=10) - Full Analysis Set**



**A-MA.1.3004.15.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Constipation by Sex (MID=10) - Full Analysis Set**




**A-MA.1.3004.15.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Constipation by Region (MID=10) - Full Analysis Set**






**A-MA.1.3004.15.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Constipation by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




### A-MA.1.3004.16.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Diarrhoea (MID=10) - Full Analysis Set


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	98 / 254	123 / 253	87.5	0.765 [0.584, 1.001]
GM03 – FAST	14 / 56	20 / 58	12.5	0.408 [0.200, 0.834]
<b>Total</b>	<b>112 / 310</b>	<b>143 / 311</b>	<b>100</b>	<b>0.707 [0.550, 0.910]</b>
Heterogeneity	Q = 2.61 (df = 1)	p = 0.1064	I <sup>2</sup> = 61.6%	p(Effect) = 0.0071




**A-MA.1.3004.16.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Diarrhoea by Age Group 1 (MID=10) - Full Analysis Set**




**A-MA.1.3004.16.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Diarrhoea by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.16.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Diarrhoea by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.16.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Diarrhoea by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




**A-MA.1.3004.17.1: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Financial Difficulties (MID=10) - Full Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	99 / 254	96 / 253	81.9	1.063 [0.802, 1.410]
GM03 – FAST	25 / 56	20 / 58	18.1	1.242 [0.682, 2.265]
<b>Total</b>	<b>124 / 310</b>	<b>116 / 311</b>	<b>100</b>	<b>1.093 [0.847, 1.411]</b>
Heterogeneity	Q = 0.21 (df = 1)	p = 0.6455	I <sup>2</sup> = 0.0%	p(Effect) = 0.4932




**A-MA.1.3004.17.2: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Financial Difficulties by Age Group 1 (MID=10) - Full Analysis Set**







**A-MA.1.3004.17.3: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Financial Difficulties by Sex (MID=10) - Full Analysis Set**



**A-MA.1.3004.17.4: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Financial Difficulties by Region (MID=10) - Full Analysis Set**




**A-MA.1.3004.17.5: EORTC QLQ-C30 - Forest Plot for Hazard Ratio of Time to First Deterioration of Financial Difficulties by Number of Organs with Metastatic Sites (MID=10) - Full Analysis Set**




## **Sicherheit**

**A-MA.1.2001.01.1: Forest Plot for Hazard Ratio of TEAEs - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	251 / 254	244 / 249	81.8	2.242 [1.856, 2.709]
GM03 – FAST	55 / 55	57 / 57	18.2	1.420 [0.951, 2.120]
<b>Total</b>	<b>306 / 309</b>	<b>301 / 306</b>	<b>100</b>	<b>2.063 [1.739, 2.448]</b>
Heterogeneity	Q = 4.08 (df = 1)	p = 0.0434	I <sup>2</sup> = 75.5%	p(Effect) < 0.0001




**A-MA.1.2001.01.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Safety Analysis Set**



**A-MA.1.2001.01.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Safety Analysis Set**




**A-MA.1.2001.01.4: Forest Plot for Hazard Ratio of TEAEs by Region - Safety Analysis Set**






### A-MA.1.2001.01.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Safety Analysis Set




**A-MA.1.2001.03.1: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq$  3) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	186 / 254	175 / 249	83.3	1.229 [0.997, 1.515]
GM03 – FAST	41 / 55	34 / 57	16.7	1.182 [0.741, 1.884]
<b>Total</b>	<b>227 / 309</b>	<b>209 / 306</b>	<b>100</b>	<b>1.221 [1.009, 1.478]</b>
Heterogeneity	Q = 0.02 (df = 1)	p = 0.8812	I <sup>2</sup> = 0.0%	p(Effect) = 0.0404




**A-MA.1.2001.03.2: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq$  3) by Age Group 1 - Safety Analysis Set**




**A-MA.1.2001.03.3: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade >= 3) by Sex - Safety Analysis Set**



**A-MA.1.2001.03.4: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade >= 3) by Region - Safety Analysis Set**




**A-MA.1.2001.03.5: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Number of Organs with Metastatic Sites - Safety Analysis Set**




**A-MA.1.2001.04.1: Forest Plot for Hazard Ratio of TESAEs - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	123 / 254	126 / 249	89.1	0.972 [0.756, 1.251]
GM03 – FAST	16 / 55	14 / 57	10.9	1.241 [0.605, 2.546]
<b>Total</b>	<b>139 / 309</b>	<b>140 / 306</b>	<b>100</b>	<b>0.998 [0.787, 1.266]</b>
Heterogeneity	Q = 0.40 (df = 1)	p = 0.5294	I <sup>2</sup> = 0.0%	p(Effect) = 0.9890




**A-MA.1.2001.04.2: Forest Plot for Hazard Ratio of TESAEs by Age Group 1 - Safety Analysis Set**







**A-MA.1.2001.04.3: Forest Plot for Hazard Ratio of TESAEs by Sex - Safety Analysis Set**



**A-MA.1.2001.04.4: Forest Plot for Hazard Ratio of TESAEs by Region - Safety Analysis Set**




**A-MA.1.2001.04.5: Forest Plot for Hazard Ratio of TESAEs by Number of Organs with Metastatic Sites - Safety Analysis Set**




**A-MA.1.2001.05.1: Forest Plot for Hazard Ratio of Permanent Treatment Discontinuation due to TEAEs - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	81 / 254	64 / 249	87.1	1.291 [0.928, 1.796]
GM03 – FAST	11 / 55	11 / 57	12.9	0.965 [0.409, 2.274]
<b>Total</b>	<b>92 / 309</b>	<b>75 / 306</b>	<b>100</b>	<b>1.243 [0.914, 1.692]</b>
Heterogeneity	Q = 0.39 (df = 1)	p = 0.5348	I <sup>2</sup> = 0.0%	p(Effect) = 0.1658




**A-MA.1.2001.05.2: Forest Plot for Hazard Ratio of Permanent Treatment Discontinuation due to TEAEs by Age Group 1 - Safety Analysis Set**




### A-MA.1.2001.05.3: Forest Plot for Hazard Ratio of Permanent Treatment Discontinuation due to TEAEs by Sex - Safety Analysis Set



**A-MA.1.2001.05.4: Forest Plot for Hazard Ratio of Permanent Treatment Discontinuation due to TEAEs by Region - Safety Analysis Set**




**A-MA.1.2001.05.5: Forest Plot for Hazard Ratio of Permanent Treatment Discontinuation due to TEAEs by Number of Organs with Metastatic Sites - Safety Analysis Set**






**A-MA.1.2001.06.1: Forest Plot for Hazard Ratio of TEAEs - Blood And Lymphatic System Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	134 / 254	127 / 249	78.2	1.113 [0.872, 1.421]
GM03 – FAST	39 / 55	35 / 57	21.8	1.235 [0.778, 1.961]
<b>Total</b>	<b>173 / 309</b>	<b>162 / 306</b>	<b>100</b>	<b>1.139 [0.917, 1.413]</b>
Heterogeneity	Q = 0.15 (df = 1)	p = 0.6966	I <sup>2</sup> = 0.0%	p(Effect) = 0.2388




**A-MA.1.2001.07.1: Forest Plot for Hazard Ratio of TEAEs - Anaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	93 / 254	92 / 249	79.4	0.976 [0.731, 1.303]
GM03 – FAST	26 / 55	24 / 57	20.6	1.100 [0.623, 1.941]
<b>Total</b>	<b>119 / 309</b>	<b>116 / 306</b>	<b>100</b>	<b>1.000 [0.773, 1.294]</b>
Heterogeneity	Q = 0.14 (df = 1)	p = 0.7131	I <sup>2</sup> = 0.0%	p(Effect) = 0.9982




**A-MA.1.2001.08.1: Forest Plot for Hazard Ratio of TEAEs - Leukopenia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	17 / 254	8 / 249	56.9	2.090 [0.901, 4.852]
GM03 – FAST	10 / 55	7 / 57	43.1	1.430 [0.544, 3.758]
<b>Total</b>	<b>27 / 309</b>	<b>15 / 306</b>	<b>100</b>	<b>1.774 [0.941, 3.347]</b>
Heterogeneity	Q = 0.34 (df = 1)	p = 0.5617	I <sup>2</sup> = 0.0%	p(Effect) = 0.0766




### A-MA.1.2001.09.1: Forest Plot for Hazard Ratio of TEAEs - Neutropenia (PT with Incidence $\geq 10$ Patients) - Safety Analysis Set


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	50 / 254	35 / 249	65.3	1.491 [0.967, 2.300]
GM03 – FAST	26 / 55	19 / 57	34.7	1.496 [0.826, 2.708]
<b>Total</b>	<b>76 / 309</b>	<b>54 / 306</b>	<b>100</b>	<b>1.493 [1.052, 2.118]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9929	I <sup>2</sup> = 0.0%	p(Effect) = 0.0249




**A-MA.1.2001.09.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.09.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.09.4: Forest Plot for Hazard Ratio of TEAEs by Region - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.09.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.10.1: Forest Plot for Hazard Ratio of TEAEs - Thrombocytopenia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	28 / 254	31 / 249	78.6	0.896 [0.537, 1.497]
GM03 – FAST	9 / 55	8 / 57	21.4	1.065 [0.399, 2.843]
<b>Total</b>	<b>37 / 309</b>	<b>39 / 306</b>	<b>100</b>	<b>0.930 [0.590, 1.465]</b>
Heterogeneity	Q = 0.09 (df = 1)	p = 0.7598	I <sup>2</sup> = 0.0%	p(Effect) = 0.7535




**A-MA.1.2001.11.1: Forest Plot for Hazard Ratio of TEAEs - Cardiac Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	24 / 254	31 / 249	83.8	0.701 [0.408, 1.204]
GM03 – FAST	5 / 55	7 / 57	16.2	0.559 [0.163, 1.917]
<b>Total</b>	<b>29 / 309</b>	<b>38 / 306</b>	<b>100</b>	<b>0.676 [0.412, 1.109]</b>
Heterogeneity	Q = 0.11 (df = 1)	p = 0.7417	I <sup>2</sup> = 0.0%	p(Effect) = 0.1211




**A-MA.1.2001.12.1: Forest Plot for Hazard Ratio of TEAEs - Sinus Bradycardia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.13.1: Forest Plot for Hazard Ratio of TEAEs - Sinus Tachycardia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	6 / 249	100	0.853 [0.259, 2.803]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>5 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>0.853 [0.259, 2.806]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.7936




**A-MA.1.2001.14.1: Forest Plot for Hazard Ratio of TEAEs - Gastrointestinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	234 / 254	199 / 249	80.5	2.311 [1.896, 2.816]
GM03 – FAST	52 / 55	51 / 57	19.5	1.674 [1.120, 2.502]
<b>Total</b>	<b>286 / 309</b>	<b>250 / 306</b>	<b>100</b>	<b>2.170 [1.817, 2.592]</b>
Heterogeneity	Q = 1.99 (df = 1)	p = 0.1582	I <sup>2</sup> = 49.8%	p(Effect) < 0.0001




**A-MA.1.2001.14.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Gastrointestinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.14.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Gastrointestinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.14.4: Forest Plot for Hazard Ratio of TEAEs by Region - Gastrointestinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.14.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Gastrointestinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.15.1: Forest Plot for Hazard Ratio of TEAEs - Abdominal Discomfort (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	8 / 249	85.7	0.586 [0.189, 1.820]
GM03 – FAST	1 / 55	1 / 57	14.3	1.200 [0.075, 19.312]
<b>Total</b>	<b>7 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>0.649 [0.227, 1.852]</b>
Heterogeneity	Q = 0.22 (df = 1)	p = 0.6393	I <sup>2</sup> = 0.0%	p(Effect) = 0.4192




**A-MA.1.2001.16.1: Forest Plot for Hazard Ratio of TEAEs - Abdominal Distension (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	15 / 254	15 / 249	100	0.952 [0.464, 1.956]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>16 / 309</b>	<b>15 / 306</b>	<b>100</b>	<b>0.952 [0.464, 1.955]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.8934




**A-MA.1.2001.17.1: Forest Plot for Hazard Ratio of TEAEs - Abdominal Pain (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	41 / 254	56 / 249	85.5	0.670 [0.446, 1.008]
GM03 – FAST	10 / 55	7 / 57	14.5	1.332 [0.496, 3.581]
<b>Total</b>	<b>51 / 309</b>	<b>63 / 306</b>	<b>100</b>	<b>0.740 [0.508, 1.079]</b>
Heterogeneity	Q = 1.59 (df = 1)	p = 0.2078	I <sup>2</sup> = 37.0%	p(Effect) = 0.1181




**A-MA.1.2001.18.1: Forest Plot for Hazard Ratio of TEAEs - Abdominal Pain Upper (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	24 / 254	13 / 249	72.7	1.896 [0.946, 3.803]
GM03 – FAST	5 / 55	12 / 57	27.3	0.307 [0.099, 0.957]
<b>Total</b>	<b>29 / 309</b>	<b>25 / 306</b>	<b>100</b>	<b>1.153 [0.637, 2.086]</b>
Heterogeneity	Q = 7.19 (df = 1)	p = 0.0073	I <sup>2</sup> = 86.1%	p(Effect) = 0.6385




**A-MA.1.2001.19.1: Forest Plot for Hazard Ratio of TEAEs - Ascites (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	9 / 254	17 / 249	84.1	0.421 [0.181, 0.979]
GM03 – FAST	2 / 55	4 / 57	15.9	0.118 [0.017, 0.822]
<b>Total</b>	<b>11 / 309</b>	<b>21 / 306</b>	<b>100</b>	<b>0.344 [0.159, 0.745]</b>
Heterogeneity	Q = 1.39 (df = 1)	p = 0.2385	I <sup>2</sup> = 28.0%	p(Effect) = 0.0069



**A-MA.1.2001.19.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Ascites (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.19.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Ascites (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.19.4: Forest Plot for Hazard Ratio of TEAEs by Region - Ascites (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.19.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Ascites (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.20.1: Forest Plot for Hazard Ratio of TEAEs - Constipation (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	40 / 254	53 / 249	93.8	0.736 [0.486, 1.115]
GM03 – FAST	3 / 55	4 / 57	6.2	0.595 [0.118, 2.999]
<b>Total</b>	<b>43 / 309</b>	<b>57 / 306</b>	<b>100</b>	<b>0.726 [0.486, 1.086]</b>
Heterogeneity	Q = 0.06 (df = 1)	p = 0.8029	I <sup>2</sup> = 0.0%	p(Effect) = 0.1193




**A-MA.1.2001.21.1: Forest Plot for Hazard Ratio of TEAEs - Diarrhoea (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	83 / 254	87 / 249	87.2	0.902 [0.667, 1.220]
GM03 – FAST	9 / 55	20 / 57	12.8	0.387 [0.176, 0.850]
<b>Total</b>	<b>92 / 309</b>	<b>107 / 306</b>	<b>100</b>	<b>0.809 [0.610, 1.073]</b>
Heterogeneity	Q = 3.87 (df = 1)	p = 0.0492	I <sup>2</sup> = 74.1%	p(Effect) = 0.1412




**A-MA.1.2001.22.1: Forest Plot for Hazard Ratio of TEAEs - Dry Mouth (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	2 / 249	100	2.580 [0.498, 13.365]
GM03 – FAST	0 / 55	4 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>5 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>2.580 [0.498, 13.366]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2588




**A-MA.1.2001.23.1: Forest Plot for Hazard Ratio of TEAEs - Dyspepsia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	14 / 254	9 / 249	80.0	1.496 [0.611, 3.662]
GM03 – FAST	3 / 55	3 / 57	20.0	0.648 [0.108, 3.884]
<b>Total</b>	<b>17 / 309</b>	<b>12 / 306</b>	<b>100</b>	<b>1.266 [0.568, 2.819]</b>
Heterogeneity	Q = 0.67 (df = 1)	p = 0.4129	I <sup>2</sup> = 0.0%	p(Effect) = 0.5643




**A-MA.1.2001.24.1: Forest Plot for Hazard Ratio of TEAEs - Dysphagia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	11 / 254	9 / 249	84.8	1.168 [0.474, 2.880]
GM03 – FAST	1 / 55	6 / 57	15.2	0.161 [0.019, 1.342]
<b>Total</b>	<b>12 / 309</b>	<b>15 / 306</b>	<b>100</b>	<b>0.864 [0.376, 1.982]</b>
Heterogeneity	Q = 2.82 (df = 1)	p = 0.0930	I <sup>2</sup> = 64.6%	p(Effect) = 0.7297



**A-MA.1.2001.25.1: Forest Plot for Hazard Ratio of TEAEs - Gastroesophageal Reflux Disease (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	5 / 249	100	1.920 [0.652, 5.654]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>11 / 309</b>	<b>5 / 306</b>	<b>100</b>	<b>1.920 [0.652, 5.654]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2365






**A-MA.1.2001.26.1: Forest Plot for Hazard Ratio of TEAEs - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	175 / 254	125 / 249	76.3	1.961 [1.554, 2.477]
GM03 – FAST	46 / 55	44 / 57	23.7	1.364 [0.898, 2.074]
<b>Total</b>	<b>221 / 309</b>	<b>169 / 306</b>	<b>100</b>	<b>1.799 [1.468, 2.206]</b>
Heterogeneity	Q = 2.21 (df = 1)	p = 0.1375	I <sup>2</sup> = 54.7%	p(Effect) < 0.0001




**A-MA.1.2001.26.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Nausea (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**




**A-MA.1.2001.26.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.26.4: Forest Plot for Hazard Ratio of TEAEs by Region - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.26.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.27.1: Forest Plot for Hazard Ratio of TEAEs - Salivary Hypersecretion (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	2 / 249	65.1	3.693 [0.766, 17.797]
GM03 – FAST	5 / 55	1 / 57	34.9	5.289 [0.618, 45.292]
<b>Total</b>	<b>12 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>4.186 [1.177, 14.890]</b>
Heterogeneity	Q = 0.07 (df = 1)	p = 0.7914	I <sup>2</sup> = 0.0%	p(Effect) = 0.0270



**A-MA.1.2001.27.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Salivary Hypersecretion (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.27.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Salivary Hypersecretion (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.27.4: Forest Plot for Hazard Ratio of TEAEs by Region - Salivary Hypersecretion (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.27.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Salivary Hypersecretion (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.28.1: Forest Plot for Hazard Ratio of TEAEs - Stomatitis (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	7 / 249	73.4	1.056 [0.380, 2.941]
GM03 – FAST	2 / 55	4 / 57	26.6	0.498 [0.091, 2.720]
<b>Total</b>	<b>10 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>0.865 [0.360, 2.077]</b>
Heterogeneity	Q = 0.55 (df = 1)	p = 0.4576	I <sup>2</sup> = 0.0%	p(Effect) = 0.7447




**A-MA.1.2001.29.1: Forest Plot for Hazard Ratio of TEAEs - Upper Gastrointestinal Haemorrhage (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	5 / 249	100	1.695 [0.554, 5.189]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>5 / 306</b>	<b>100</b>	<b>1.695 [0.554, 5.187]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.3552




**A-MA.1.2001.30.1: Forest Plot for Hazard Ratio of TEAEs - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	168 / 254	79 / 249	74.4	3.305 [2.521, 4.331]
GM03 – FAST	42 / 55	34 / 57	25.6	1.861 [1.173, 2.952]
<b>Total</b>	<b>210 / 309</b>	<b>113 / 306</b>	<b>100</b>	<b>2.853 [2.259, 3.604]</b>
Heterogeneity	Q = 4.43 (df = 1)	p = 0.0354	I <sup>2</sup> = 77.4%	p(Effect) < 0.0001




**A-MA.1.2001.30.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.30.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.30.4: Forest Plot for Hazard Ratio of TEAEs by Region - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.30.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Vomiting (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**




**A-MA.1.2001.31.1: Forest Plot for Hazard Ratio of TEAEs - General Disorders And Administration Site Conditions (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	144 / 254	125 / 249	77.2	1.189 [0.933, 1.515]
GM03 – FAST	41 / 55	39 / 57	22.8	0.959 [0.614, 1.499]
<b>Total</b>	<b>185 / 309</b>	<b>164 / 306</b>	<b>100</b>	<b>1.132 [0.915, 1.401]</b>
Heterogeneity	Q = 0.69 (df = 1)	p = 0.4067	I <sup>2</sup> = 0.0%	p(Effect) = 0.2533




**A-MA.1.2001.32.1: Forest Plot for Hazard Ratio of TEAEs - Asthenia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	34 / 254	32 / 249	73.9	1.068 [0.656, 1.739]
GM03 – FAST	14 / 55	13 / 57	26.1	0.806 [0.355, 1.829]
<b>Total</b>	<b>48 / 309</b>	<b>45 / 306</b>	<b>100</b>	<b>0.992 [0.653, 1.509]</b>
Heterogeneity	Q = 0.33 (df = 1)	p = 0.5630	I <sup>2</sup> = 0.0%	p(Effect) = 0.9711




**A-MA.1.2001.33.1: Forest Plot for Hazard Ratio of TEAEs - Chest Discomfort (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	7 / 249	100	1.312 [0.486, 3.539]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>10 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>1.312 [0.486, 3.540]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5919




**A-MA.1.2001.34.1: Forest Plot for Hazard Ratio of TEAEs - Chills (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	11 / 254	5 / 249	83.7	2.229 [0.774, 6.421]
GM03 – FAST	2 / 55	1 / 57	16.3	2.103 [0.191, 23.190]
<b>Total</b>	<b>13 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>2.208 [0.839, 5.813]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9653	I <sup>2</sup> = 0.0%	p(Effect) = 0.1088




**A-MA.1.2001.35.1: Forest Plot for Hazard Ratio of TEAEs - Fatigue (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	35 / 254	42 / 249	74.8	0.773 [0.493, 1.212]
GM03 – FAST	16 / 55	11 / 57	25.2	1.414 [0.651, 3.072]
<b>Total</b>	<b>51 / 309</b>	<b>53 / 306</b>	<b>100</b>	<b>0.900 [0.610, 1.328]</b>
Heterogeneity	Q = 1.74 (df = 1)	p = 0.1869	I <sup>2</sup> = 42.6%	p(Effect) = 0.5949




**A-MA.1.2001.36.1: Forest Plot for Hazard Ratio of TEAEs - Malaise (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	31 / 254	22 / 249	100	1.416 [0.816, 2.457]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>31 / 309</b>	<b>22 / 306</b>	<b>100</b>	<b>1.416 [0.816, 2.457]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2161



**A-MA.1.2001.37.1: Forest Plot for Hazard Ratio of TEAEs - Mucosal Inflammation (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	6 / 249	100	1.140 [0.383, 3.393]
GM03 – FAST	0 / 55	2 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>8 / 306</b>	<b>100</b>	<b>1.140 [0.383, 3.393]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.8139






**A-MA.1.2001.38.1: Forest Plot for Hazard Ratio of TEAEs - Oedema Peripheral (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	26 / 254	6 / 249	58.6	4.489 [1.843, 10.934]
GM03 – FAST	8 / 55	6 / 57	41.4	1.311 [0.454, 3.781]
<b>Total</b>	<b>34 / 309</b>	<b>12 / 306</b>	<b>100</b>	<b>2.698 [1.364, 5.334]</b>
Heterogeneity	Q = 3.04 (df = 1)	p = 0.0813	I <sup>2</sup> = 67.1%	p(Effect) = 0.0043




**A-MA.1.2001.38.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Oedema Peripheral (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.38.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Oedema Peripheral (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.38.4: Forest Plot for Hazard Ratio of TEAEs by Region - Oedema Peripheral (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**




**A-MA.1.2001.38.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Oedema Peripheral (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.39.1: Forest Plot for Hazard Ratio of TEAEs - Pain (PT with Incidence >=10 Patients)  
- Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	1 / 249	39.9	4.063 [0.453, 36.442]
GM03 – FAST	2 / 55	3 / 57	60.1	0.694 [0.116, 4.151]
<b>Total</b>	<b>7 / 309</b>	<b>4 / 306</b>	<b>100</b>	<b>1.406 [0.351, 5.622]</b>
Heterogeneity	Q = 1.50 (df = 1)	p = 0.2211	I <sup>2</sup> = 33.2%	p(Effect) = 0.6303




**A-MA.1.2001.40.1: Forest Plot for Hazard Ratio of TEAEs - Pyrexia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	36 / 254	23 / 249	74.2	1.526 [0.900, 2.587]
GM03 – FAST	8 / 55	12 / 57	25.8	0.652 [0.266, 1.597]
<b>Total</b>	<b>44 / 309</b>	<b>35 / 306</b>	<b>100</b>	<b>1.226 [0.778, 1.932]</b>
Heterogeneity	Q = 2.57 (df = 1)	p = 0.1091	I <sup>2</sup> = 61.1%	p(Effect) = 0.3804



**A-MA.1.2001.41.1: Forest Plot for Hazard Ratio of TEAEs - Hepatobiliary Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	17 / 254	15 / 249	82.2	1.133 [0.563, 2.281]
GM03 – FAST	4 / 55	4 / 57	17.8	0.741 [0.165, 3.325]
<b>Total</b>	<b>21 / 309</b>	<b>19 / 306</b>	<b>100</b>	<b>1.050 [0.557, 1.980]</b>
Heterogeneity	Q = 0.25 (df = 1)	p = 0.6154	I <sup>2</sup> = 0.0%	p(Effect) = 0.8793






**A-MA.1.2001.42.1: Forest Plot for Hazard Ratio of TEAEs - Hyperbilirubinaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	3 / 254	3 / 249	69.2	1.040 [0.209, 5.170]
GM03 – FAST	2 / 55	2 / 57	30.8	0.511 [0.046, 5.646]
<b>Total</b>	<b>5 / 309</b>	<b>5 / 306</b>	<b>100</b>	<b>0.836 [0.220, 3.174]</b>
Heterogeneity	Q = 0.23 (df = 1)	p = 0.6300	I <sup>2</sup> = 0.0%	p(Effect) = 0.7920




**A-MA.1.2001.43.1: Forest Plot for Hazard Ratio of TEAEs - Immune System Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	7 / 249	83.7	0.981 [0.340, 2.828]
GM03 – FAST	2 / 55	1 / 57	16.3	2.102 [0.191, 23.186]
<b>Total</b>	<b>9 / 309</b>	<b>8 / 306</b>	<b>100</b>	<b>1.111 [0.422, 2.927]</b>
Heterogeneity	Q = 0.32 (df = 1)	p = 0.5690	I <sup>2</sup> = 0.0%	p(Effect) = 0.8317




**A-MA.1.2001.44.1: Forest Plot for Hazard Ratio of TEAEs - Infections And Infestations (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	78 / 254	70 / 249	92.9	1.031 [0.743, 1.430]
GM03 – FAST	9 / 55	7 / 57	7.1	0.574 [0.175, 1.884]
<b>Total</b>	<b>87 / 309</b>	<b>77 / 306</b>	<b>100</b>	<b>0.989 [0.722, 1.356]</b>
Heterogeneity	Q = 0.87 (df = 1)	p = 0.3517	I <sup>2</sup> = 0.0%	p(Effect) = 0.9466




**A-MA.1.2001.45.1: Forest Plot for Hazard Ratio of TEAEs - Covid-19 (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	15 / 254	12 / 249	100	0.933 [0.412, 2.112]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>15 / 309</b>	<b>12 / 306</b>	<b>100</b>	<b>0.933 [0.412, 2.112]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.8679




**A-MA.1.2001.46.1: Forest Plot for Hazard Ratio of TEAEs - Pneumonia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	12 / 254	11 / 249	100	1.283 [0.553, 2.977]
GM03 – FAST	1 / 55	2 / 57	NC	0.001 [0.001, NC]
<b>Total</b>	<b>13 / 309</b>	<b>13 / 306</b>	<b>100</b>	<b>1.283 [0.553, 2.977]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5617




**A-MA.1.2001.47.1: Forest Plot for Hazard Ratio of TEAEs - Urinary Tract Infection (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	6 / 249	100	1.070 [0.356, 3.212]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.070 [0.356, 3.214]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9040




**A-MA.1.2001.48.1: Forest Plot for Hazard Ratio of TEAEs - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	31 / 254	15 / 249	92.9	1.895 [1.015, 3.539]
GM03 – FAST	4 / 55	1 / 57	7.1	3.115 [0.324, 29.966]
<b>Total</b>	<b>35 / 309</b>	<b>16 / 306</b>	<b>100</b>	<b>1.963 [1.075, 3.584]</b>
Heterogeneity	Q = 0.17 (df = 1)	p = 0.6782	I <sup>2</sup> = 0.0%	p(Effect) = 0.0281




**A-MA.1.2001.48.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**







**A-MA.1.2001.48.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.48.4: Forest Plot for Hazard Ratio of TEAEs by Region - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.48.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.49.1: Forest Plot for Hazard Ratio of TEAEs - Infusion Related Reaction (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	11 / 254	2 / 249	100	5.357 [1.186, 24.200]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>12 / 309</b>	<b>2 / 306</b>	<b>100</b>	<b>5.357 [1.186, 24.198]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.0291




**A-MA.1.2001.49.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Infusion Related Reaction (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.49.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Infusion Related Reaction (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.49.4: Forest Plot for Hazard Ratio of TEAEs by Region - Infusion Related Reaction (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.49.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Infusion Related Reaction (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.50.1: Forest Plot for Hazard Ratio of TEAEs - Investigations (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	154 / 254	152 / 249	83.3	1.035 [0.825, 1.299]
GM03 – FAST	31 / 55	33 / 57	16.7	0.791 [0.477, 1.313]
<b>Total</b>	<b>185 / 309</b>	<b>185 / 306</b>	<b>100</b>	<b>0.989 [0.804, 1.217]</b>
Heterogeneity	Q = 0.90 (df = 1)	p = 0.3422	I <sup>2</sup> = 0.0%	p(Effect) = 0.9201




**A-MA.1.2001.51.1: Forest Plot for Hazard Ratio of TEAEs - Alanine Aminotransferase Increased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	48 / 254	53 / 249	92.6	0.898 [0.607, 1.330]
GM03 – FAST	4 / 55	6 / 57	7.4	0.545 [0.136, 2.191]
<b>Total</b>	<b>52 / 309</b>	<b>59 / 306</b>	<b>100</b>	<b>0.866 [0.593, 1.262]</b>
Heterogeneity	Q = 0.46 (df = 1)	p = 0.4979	I <sup>2</sup> = 0.0%	p(Effect) = 0.4533




**A-MA.1.2001.52.1: Forest Plot for Hazard Ratio of TEAEs - Aspartate Aminotransferase Increased (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	63 / 254	75 / 249	92.7	0.811 [0.579, 1.137]
GM03 – FAST	6 / 55	7 / 57	7.3	0.624 [0.187, 2.081]
<b>Total</b>	<b>69 / 309</b>	<b>82 / 306</b>	<b>100</b>	<b>0.796 [0.575, 1.101]</b>
Heterogeneity	Q = 0.17 (df = 1)	p = 0.6813	I <sup>2</sup> = 0.0%	p(Effect) = 0.1680




**A-MA.1.2001.53.1: Forest Plot for Hazard Ratio of TEAEs - Blood Alkaline Phosphatase Increased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	14 / 254	20 / 249	88.4	0.647 [0.325, 1.288]
GM03 – FAST	3 / 55	3 / 57	11.6	0.436 [0.065, 2.905]
<b>Total</b>	<b>17 / 309</b>	<b>23 / 306</b>	<b>100</b>	<b>0.618 [0.324, 1.181]</b>
Heterogeneity	Q = 0.15 (df = 1)	p = 0.7019	I <sup>2</sup> = 0.0%	p(Effect) = 0.1451




**A-MA.1.2001.54.1: Forest Plot for Hazard Ratio of TEAEs - Blood Bilirubin Increased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	24 / 254	23 / 249	100	0.948 [0.529, 1.699]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>25 / 309</b>	<b>23 / 306</b>	<b>100</b>	<b>0.948 [0.529, 1.699]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.8576




**A-MA.1.2001.55.1: Forest Plot for Hazard Ratio of TEAEs - Blood Creatinine Increased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	4 / 249	88.8	1.779 [0.519, 6.098]
GM03 – FAST	1 / 55	1 / 57	11.2	0.231 [0.007, 7.239]
<b>Total</b>	<b>9 / 309</b>	<b>5 / 306</b>	<b>100</b>	<b>1.416 [0.443, 4.520]</b>
Heterogeneity	Q = 1.18 (df = 1)	p = 0.2773	I <sup>2</sup> = 15.3%	p(Effect) = 0.5573




**A-MA.1.2001.56.1: Forest Plot for Hazard Ratio of TEAEs - Electrocardiogram Qt Prolonged (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.57.1: Forest Plot for Hazard Ratio of TEAEs - Gamma-Glutamyltransferase Increased (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	9 / 254	10 / 249	63.4	0.887 [0.357, 2.203]
GM03 – FAST	7 / 55	5 / 57	36.6	1.165 [0.352, 3.856]
<b>Total</b>	<b>16 / 309</b>	<b>15 / 306</b>	<b>100</b>	<b>0.980 [0.475, 2.022]</b>
Heterogeneity	Q = 0.13 (df = 1)	p = 0.7223	I <sup>2</sup> = 0.0%	p(Effect) = 0.9567






**A-MA.1.2001.58.1: Forest Plot for Hazard Ratio of TEAEs - Lymphocyte Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	6 / 249	100	1.342 [0.464, 3.882]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>9 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.342 [0.464, 3.882]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5872




**A-MA.1.2001.59.1: Forest Plot for Hazard Ratio of TEAEs - Neutrophil Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	71 / 254	59 / 249	98.5	1.160 [0.819, 1.643]
GM03 – FAST	2 / 55	1 / 57	1.5	1.251 [0.078, 20.143]
<b>Total</b>	<b>73 / 309</b>	<b>60 / 306</b>	<b>100</b>	<b>1.161 [0.822, 1.640]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9578	I <sup>2</sup> = 0.0%	p(Effect) = 0.3960




**A-MA.1.2001.60.1: Forest Plot for Hazard Ratio of TEAEs - Platelet Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	61 / 254	62 / 249	100	0.964 [0.676, 1.375]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>62 / 309</b>	<b>62 / 306</b>	<b>100</b>	<b>0.964 [0.676, 1.375]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.8396




**A-MA.1.2001.61.1: Forest Plot for Hazard Ratio of TEAEs - Weight Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	51 / 254	25 / 249	66.8	2.072 [1.279, 3.357]
GM03 – FAST	20 / 55	16 / 57	33.2	1.102 [0.556, 2.183]
<b>Total</b>	<b>71 / 309</b>	<b>41 / 306</b>	<b>100</b>	<b>1.680 [1.133, 2.492]</b>
Heterogeneity	Q = 2.19 (df = 1)	p = 0.1392	I <sup>2</sup> = 54.3%	p(Effect) = 0.0099




**A-MA.1.2001.61.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Weight Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.61.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Weight Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.61.4: Forest Plot for Hazard Ratio of TEAEs by Region - Weight Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.61.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Weight Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.62.1: Forest Plot for Hazard Ratio of TEAEs - Weight Increased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	5 / 249	100	0.980 [0.283, 3.393]
GM03 – FAST	2 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>5 / 306</b>	<b>100</b>	<b>0.980 [0.283, 3.393]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9746




**A-MA.1.2001.63.1: Forest Plot for Hazard Ratio of TEAEs - White Blood Cell Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	51 / 254	40 / 249	97.8	1.240 [0.819, 1.878]
GM03 – FAST	2 / 55	1 / 57	2.2	1.041 [0.065, 16.650]
<b>Total</b>	<b>53 / 309</b>	<b>41 / 306</b>	<b>100</b>	<b>1.235 [0.819, 1.862]</b>
Heterogeneity	Q = 0.01 (df = 1)	p = 0.9027	I <sup>2</sup> = 0.0%	p(Effect) = 0.3129




**A-MA.1.2001.64.1: Forest Plot for Hazard Ratio of TEAEs - Metabolism And Nutrition Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	155 / 254	141 / 249	91.5	1.252 [0.993, 1.577]
GM03 – FAST	16 / 55	15 / 57	8.5	0.791 [0.370, 1.693]
<b>Total</b>	<b>171 / 309</b>	<b>156 / 306</b>	<b>100</b>	<b>1.204 [0.965, 1.502]</b>
Heterogeneity	Q = 1.28 (df = 1)	p = 0.2575	I <sup>2</sup> = 22.0%	p(Effect) = 0.0997




**A-MA.1.2001.65.1: Forest Plot for Hazard Ratio of TEAEs - Decreased Appetite (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	105 / 254	86 / 249	92.3	1.352 [1.013, 1.804]
GM03 – FAST	7 / 55	11 / 57	7.7	0.527 [0.195, 1.428]
<b>Total</b>	<b>112 / 309</b>	<b>97 / 306</b>	<b>100</b>	<b>1.257 [0.953, 1.658]</b>
Heterogeneity	Q = 3.17 (df = 1)	p = 0.0748	I <sup>2</sup> = 68.5%	p(Effect) = 0.1060




**A-MA.1.2001.66.1: Forest Plot for Hazard Ratio of TEAEs - Dehydration (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	4 / 249	100	1.509 [0.425, 5.352]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>6 / 309</b>	<b>4 / 306</b>	<b>100</b>	<b>1.509 [0.425, 5.355]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5243




**A-MA.1.2001.67.1: Forest Plot for Hazard Ratio of TEAEs - Hyperglycaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	3 / 254	6 / 249	74.6	0.450 [0.111, 1.829]
GM03 – FAST	1 / 55	2 / 57	25.4	0.685 [0.062, 7.566]
<b>Total</b>	<b>4 / 309</b>	<b>8 / 306</b>	<b>100</b>	<b>0.501 [0.149, 1.679]</b>
Heterogeneity	Q = 0.09 (df = 1)	p = 0.7671	I <sup>2</sup> = 0.0%	p(Effect) = 0.2625




**A-MA.1.2001.68.1: Forest Plot for Hazard Ratio of TEAEs - Hyperuricaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	4 / 254	7 / 249	100	0.495 [0.139, 1.758]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>4 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>0.495 [0.139, 1.760]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2773




**A-MA.1.2001.69.1: Forest Plot for Hazard Ratio of TEAEs - Hypoalbuminaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	57 / 254	35 / 249	92.0	1.767 [1.158, 2.696]
GM03 – FAST	4 / 55	5 / 57	8.0	0.625 [0.149, 2.621]
<b>Total</b>	<b>61 / 309</b>	<b>40 / 306</b>	<b>100</b>	<b>1.626 [1.084, 2.439]</b>
Heterogeneity	Q = 1.86 (df = 1)	p = 0.1729	I <sup>2</sup> = 46.2%	p(Effect) = 0.0187







**A-MA.1.2001.69.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Hypoalbuminaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.69.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Hypoalbuminaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.69.4: Forest Plot for Hazard Ratio of TEAEs by Region - Hypoalbuminaemia (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**




**A-MA.1.2001.69.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Hypoalbuminaemia (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**




**A-MA.1.2001.70.1: Forest Plot for Hazard Ratio of TEAEs - Hypocalcaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	13 / 254	12 / 249	92.6	1.071 [0.488, 2.351]
GM03 – FAST	2 / 55	1 / 57	7.4	1.363 [0.085, 21.804]
<b>Total</b>	<b>15 / 309</b>	<b>13 / 306</b>	<b>100</b>	<b>1.090 [0.512, 2.323]</b>
Heterogeneity	Q = 0.03 (df = 1)	p = 0.8698	I <sup>2</sup> = 0.0%	p(Effect) = 0.8226




**A-MA.1.2001.71.1: Forest Plot for Hazard Ratio of TEAEs - Hypokalaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	37 / 254	38 / 249	100	0.924 [0.586, 1.458]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>37 / 309</b>	<b>38 / 306</b>	<b>100</b>	<b>0.924 [0.586, 1.457]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.7339




**A-MA.1.2001.72.1: Forest Plot for Hazard Ratio of TEAEs - Hyponatraemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	16 / 254	18 / 249	100	0.793 [0.396, 1.589]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>16 / 309</b>	<b>19 / 306</b>	<b>100</b>	<b>0.793 [0.396, 1.589]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5129



**A-MA.1.2001.73.1: Forest Plot for Hazard Ratio of TEAEs - Hypophosphataemia (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	7 / 249	100	1.210 [0.437, 3.352]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>1.210 [0.437, 3.351]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.7138






**A-MA.1.2001.74.1: Forest Plot for Hazard Ratio of TEAEs - Hypoproteinaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	5 / 249	100	1.253 [0.380, 4.127]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>5 / 306</b>	<b>100</b>	<b>1.253 [0.380, 4.129]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.7109




### A-MA.1.2001.75.1: Forest Plot for Hazard Ratio of TEAEs - Musculoskeletal And Connective Tissue Disorders (SOC with Incidence $\geq 10$ Patients) - Safety Analysis Set

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	37 / 254	52 / 249	86.3	0.591 [0.383, 0.909]
GM03 – FAST	6 / 55	11 / 57	13.7	0.400 [0.135, 1.185]
<b>Total</b>	<b>43 / 309</b>	<b>63 / 306</b>	<b>100</b>	<b>0.560 [0.375, 0.837]</b>
Heterogeneity	Q = 0.43 (df = 1)	p = 0.5128	I <sup>2</sup> = 0.0%	p(Effect) = 0.0047




**A-MA.1.2001.75.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Musculoskeletal And Connective Tissue Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.75.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Musculoskeletal And Connective Tissue Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.75.4: Forest Plot for Hazard Ratio of TEAEs by Region - Musculoskeletal And Connective Tissue Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.75.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Musculoskeletal And Connective Tissue Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.76.1: Forest Plot for Hazard Ratio of TEAEs - Arthralgia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	7 / 249	82.6	0.783 [0.260, 2.359]
GM03 – FAST	1 / 55	2 / 57	17.4	0.540 [0.049, 5.994]
<b>Total</b>	<b>7 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>0.734 [0.269, 2.000]</b>
Heterogeneity	Q = 0.08 (df = 1)	p = 0.7830	I <sup>2</sup> = 0.0%	p(Effect) = 0.5453




**A-MA.1.2001.77.1: Forest Plot for Hazard Ratio of TEAEs - Back Pain (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	20 / 249	89.8	0.418 [0.190, 0.919]
GM03 – FAST	1 / 55	4 / 57	10.2	0.145 [0.014, 1.508]
<b>Total</b>	<b>11 / 309</b>	<b>24 / 306</b>	<b>100</b>	<b>0.375 [0.178, 0.792]</b>
Heterogeneity	Q = 0.71 (df = 1)	p = 0.4006	I <sup>2</sup> = 0.0%	p(Effect) = 0.0101







**A-MA.1.2001.77.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Back Pain (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.77.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Back Pain (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.77.4: Forest Plot for Hazard Ratio of TEAEs by Region - Back Pain (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.77.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Back Pain (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.78.1: Forest Plot for Hazard Ratio of TEAEs - Myalgia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	2 / 254	7 / 249	60.5	0.234 [0.048, 1.140]
GM03 – FAST	2 / 55	2 / 57	39.5	1.057 [0.149, 7.504]
<b>Total</b>	<b>4 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>0.425 [0.124, 1.455]</b>
Heterogeneity	Q = 1.38 (df = 1)	p = 0.2408	I <sup>2</sup> = 27.3%	p(Effect) = 0.1729




**A-MA.1.2001.79.1: Forest Plot for Hazard Ratio of TEAEs - Pain In Extremity (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	6 / 249	100	0.958 [0.309, 2.971]
GM03 – FAST	0 / 55	3 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>6 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>0.958 [0.309, 2.971]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9408




**A-MA.1.2001.80.1: Forest Plot for Hazard Ratio of TEAEs - Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps) (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	14 / 254	20 / 249	79.0	0.658 [0.322, 1.345]
GM03 – FAST	4 / 55	6 / 57	21.0	0.504 [0.126, 2.022]
<b>Total</b>	<b>18 / 309</b>	<b>26 / 306</b>	<b>100</b>	<b>0.622 [0.330, 1.175]</b>
Heterogeneity	Q = 0.11 (df = 1)	p = 0.7378	I <sup>2</sup> = 0.0%	p(Effect) = 0.1434



**A-MA.1.2001.81.1: Forest Plot for Hazard Ratio of TEAEs - Malignant Neoplasm Progression (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	13 / 249	100	0.728 [0.306, 1.736]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>10 / 309</b>	<b>13 / 306</b>	<b>100</b>	<b>0.728 [0.306, 1.734]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.4734






**A-MA.1.2001.82.1: Forest Plot for Hazard Ratio of TEAEs - Nervous System Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	140 / 254	144 / 249	83.7	0.926 [0.733, 1.169]
GM03 – FAST	28 / 55	28 / 57	16.3	0.911 [0.536, 1.546]
<b>Total</b>	<b>168 / 309</b>	<b>172 / 306</b>	<b>100</b>	<b>0.924 [0.746, 1.143]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9559	I <sup>2</sup> = 0.0%	p(Effect) = 0.4654




**A-MA.1.2001.83.1: Forest Plot for Hazard Ratio of TEAEs - Dizziness (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	14 / 254	12 / 249	80.6	1.163 [0.537, 2.515]
GM03 – FAST	2 / 55	7 / 57	19.4	0.289 [0.060, 1.394]
<b>Total</b>	<b>16 / 309</b>	<b>19 / 306</b>	<b>100</b>	<b>0.888 [0.444, 1.775]</b>
Heterogeneity	Q = 2.43 (df = 1)	p = 0.1193	I <sup>2</sup> = 58.8%	p(Effect) = 0.7358




**A-MA.1.2001.84.1: Forest Plot for Hazard Ratio of TEAEs - Dysaesthesia (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	5 / 249	70.8	1.344 [0.426, 4.241]
GM03 – FAST	3 / 55	2 / 57	29.2	1.510 [0.252, 9.041]
<b>Total</b>	<b>10 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>1.390 [0.529, 3.657]</b>
Heterogeneity	Q = 0.01 (df = 1)	p = 0.9145	I <sup>2</sup> = 0.0%	p(Effect) = 0.5040




**A-MA.1.2001.85.1: Forest Plot for Hazard Ratio of TEAEs - Dysgeusia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.86.1: Forest Plot for Hazard Ratio of TEAEs - Headache (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	8 / 249	37.9	0.937 [0.349, 2.512]
GM03 – FAST	12 / 55	14 / 57	62.1	0.882 [0.408, 1.907]
<b>Total</b>	<b>20 / 309</b>	<b>22 / 306</b>	<b>100</b>	<b>0.902 [0.492, 1.657]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9246	I <sup>2</sup> = 0.0%	p(Effect) = 0.7406




**A-MA.1.2001.87.1: Forest Plot for Hazard Ratio of TEAEs - Hypoaesthesia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	31 / 254	30 / 249	95.8	1.015 [0.614, 1.679]
GM03 – FAST	2 / 55	1 / 57	4.2	2.092 [0.190, 23.072]
<b>Total</b>	<b>33 / 309</b>	<b>31 / 306</b>	<b>100</b>	<b>1.046 [0.640, 1.712]</b>
Heterogeneity	Q = 0.33 (df = 1)	p = 0.5632	I <sup>2</sup> = 0.0%	p(Effect) = 0.8568




**A-MA.1.2001.88.1: Forest Plot for Hazard Ratio of TEAEs - Neuropathy Peripheral (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	13 / 254	13 / 249	74.5	1.000 [0.463, 2.161]
GM03 – FAST	5 / 55	4 / 57	25.5	1.275 [0.342, 4.753]
<b>Total</b>	<b>18 / 309</b>	<b>17 / 306</b>	<b>100</b>	<b>1.064 [0.547, 2.068]</b>
Heterogeneity	Q = 0.10 (df = 1)	p = 0.7548	I <sup>2</sup> = 0.0%	p(Effect) = 0.8549



**A-MA.1.2001.89.1: Forest Plot for Hazard Ratio of TEAEs - Neurotoxicity (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	14 / 254	19 / 249	100	0.715 [0.358, 1.426]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>15 / 309</b>	<b>19 / 306</b>	<b>100</b>	<b>0.715 [0.358, 1.427]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.3414






**A-MA.1.2001.90.1: Forest Plot for Hazard Ratio of TEAEs - Paraesthesia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	13 / 254	11 / 249	61.9	1.187 [0.531, 2.652]
GM03 – FAST	7 / 55	8 / 57	38.1	0.777 [0.279, 2.166]
<b>Total</b>	<b>20 / 309</b>	<b>19 / 306</b>	<b>100</b>	<b>1.010 [0.537, 1.901]</b>
Heterogeneity	Q = 0.41 (df = 1)	p = 0.5237	I <sup>2</sup> = 0.0%	p(Effect) = 0.9755




**A-MA.1.2001.91.1: Forest Plot for Hazard Ratio of TEAEs - Peripheral Sensory Neuropathy (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	57 / 254	56 / 249	93.4	0.992 [0.685, 1.435]
GM03 – FAST	4 / 55	4 / 57	6.6	1.042 [0.260, 4.167]
<b>Total</b>	<b>61 / 309</b>	<b>60 / 306</b>	<b>100</b>	<b>0.995 [0.696, 1.423]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9465	I <sup>2</sup> = 0.0%	p(Effect) = 0.9791




**A-MA.1.2001.92.1: Forest Plot for Hazard Ratio of TEAEs - Psychiatric Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	35 / 254	27 / 249	92.5	1.255 [0.755, 2.087]
GM03 – FAST	3 / 55	3 / 57	7.5	0.676 [0.113, 4.044]
<b>Total</b>	<b>38 / 309</b>	<b>30 / 306</b>	<b>100</b>	<b>1.198 [0.735, 1.954]</b>
Heterogeneity	Q = 0.43 (df = 1)	p = 0.5144	I <sup>2</sup> = 0.0%	p(Effect) = 0.4684




**A-MA.1.2001.93.1: Forest Plot for Hazard Ratio of TEAEs - Insomnia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	28 / 254	18 / 249	94.2	1.455 [0.801, 2.644]
GM03 – FAST	2 / 55	2 / 57	5.8	0.499 [0.045, 5.509]
<b>Total</b>	<b>30 / 309</b>	<b>20 / 306</b>	<b>100</b>	<b>1.367 [0.766, 2.441]</b>
Heterogeneity	Q = 0.72 (df = 1)	p = 0.3971	I <sup>2</sup> = 0.0%	p(Effect) = 0.2901




**A-MA.1.2001.94.1: Forest Plot for Hazard Ratio of TEAEs - Renal And Urinary Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	23 / 254	21 / 249	100	1.030 [0.567, 1.871]
GM03 – FAST	1 / 55	1 / 57	NC	0.001 [0.001, NC]
<b>Total</b>	<b>24 / 309</b>	<b>22 / 306</b>	<b>100</b>	<b>1.030 [0.567, 1.871]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9227




**A-MA.1.2001.95.1: Forest Plot for Hazard Ratio of TEAEs - Proteinuria (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	4 / 249	100	1.462 [0.410, 5.205]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>6 / 309</b>	<b>4 / 306</b>	<b>100</b>	<b>1.462 [0.410, 5.209]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5580




**A-MA.1.2001.96.1: Forest Plot for Hazard Ratio of TEAEs - Reproductive System And Breast Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	8 / 249	87.2	0.663 [0.228, 1.929]
GM03 – FAST	2 / 55	1 / 57	12.8	1.202 [0.074, 19.441]
<b>Total</b>	<b>8 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>0.716 [0.264, 1.939]</b>
Heterogeneity	Q = 0.15 (df = 1)	p = 0.6959	I <sup>2</sup> = 0.0%	p(Effect) = 0.5105



**A-MA.1.2001.97.1: Forest Plot for Hazard Ratio of TEAEs - Respiratory, Thoracic And Mediastinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	57 / 254	63 / 249	80.7	0.846 [0.588, 1.216]
GM03 – FAST	14 / 55	15 / 57	19.3	0.834 [0.396, 1.753]
<b>Total</b>	<b>71 / 309</b>	<b>78 / 306</b>	<b>100</b>	<b>0.844 [0.609, 1.169]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9730	I <sup>2</sup> = 0.0%	p(Effect) = 0.3074






**A-MA.1.2001.98.1: Forest Plot for Hazard Ratio of TEAEs - Cough (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	12 / 254	15 / 249	89.7	0.788 [0.366, 1.700]
GM03 – FAST	4 / 55	1 / 57	10.3	2.939 [0.306, 28.275]
<b>Total</b>	<b>16 / 309</b>	<b>16 / 306</b>	<b>100</b>	<b>0.903 [0.436, 1.868]</b>
Heterogeneity	Q = 1.17 (df = 1)	p = 0.2803	I <sup>2</sup> = 14.2%	p(Effect) = 0.7826




**A-MA.1.2001.99.1: Forest Plot for Hazard Ratio of TEAEs - Dyspnoea (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	15 / 254	13 / 249	79.0	1.136 [0.534, 2.418]
GM03 – FAST	4 / 55	4 / 57	21.0	0.801 [0.185, 3.473]
<b>Total</b>	<b>19 / 309</b>	<b>17 / 306</b>	<b>100</b>	<b>1.056 [0.540, 2.066]</b>
Heterogeneity	Q = 0.17 (df = 1)	p = 0.6780	I <sup>2</sup> = 0.0%	p(Effect) = 0.8741




**A-MA.1.2001.100.1: Forest Plot for Hazard Ratio of TEAEs - Epistaxis (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.101.1: Forest Plot for Hazard Ratio of TEAEs - Hiccups (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	11 / 254	7 / 249	86.5	1.489 [0.577, 3.845]
GM03 – FAST	1 / 55	2 / 57	13.5	0.512 [0.046, 5.650]
<b>Total</b>	<b>12 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>1.290 [0.534, 3.117]</b>
Heterogeneity	Q = 0.65 (df = 1)	p = 0.4184	I <sup>2</sup> = 0.0%	p(Effect) = 0.5718




**A-MA.1.2001.102.1: Forest Plot for Hazard Ratio of TEAEs - Pleural Effusion (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	7 / 249	100	0.718 [0.221, 2.328]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>5 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>0.718 [0.221, 2.330]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5813




**A-MA.1.2001.103.1: Forest Plot for Hazard Ratio of TEAEs - Productive Cough (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.104.1: Forest Plot for Hazard Ratio of TEAEs - Pulmonary Embolism (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	11 / 249	100	0.502 [0.184, 1.368]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>0.502 [0.184, 1.369]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.1781



**A-MA.1.2001.105.1: Forest Plot for Hazard Ratio of TEAEs - Skin And Subcutaneous Tissue Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	86 / 254	74 / 249	79.2	1.045 [0.760, 1.437]
GM03 – FAST	24 / 55	17 / 57	20.8	1.592 [0.855, 2.965]
<b>Total</b>	<b>110 / 309</b>	<b>91 / 306</b>	<b>100</b>	<b>1.141 [0.859, 1.514]</b>
Heterogeneity	Q = 1.39 (df = 1)	p = 0.2376	I <sup>2</sup> = 28.3%	p(Effect) = 0.3632






**A-MA.1.2001.106.1: Forest Plot for Hazard Ratio of TEAEs - Alopecia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	5 / 249	26.4	1.074 [0.316, 3.643]
GM03 – FAST	16 / 55	13 / 57	73.6	1.293 [0.622, 2.689]
<b>Total</b>	<b>23 / 309</b>	<b>18 / 306</b>	<b>100</b>	<b>1.231 [0.657, 2.307]</b>
Heterogeneity	Q = 0.07 (df = 1)	p = 0.7985	I <sup>2</sup> = 0.0%	p(Effect) = 0.5163




**A-MA.1.2001.107.1: Forest Plot for Hazard Ratio of TEAEs - Palmar-Plantar Erythrodysesthesia Syndrome (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	43 / 254	49 / 249	87.0	0.823 [0.543, 1.247]
GM03 – FAST	10 / 55	5 / 57	13.0	2.274 [0.775, 6.672]
<b>Total</b>	<b>53 / 309</b>	<b>54 / 306</b>	<b>100</b>	<b>0.939 [0.637, 1.384]</b>
Heterogeneity	Q = 2.98 (df = 1)	p = 0.0843	I <sup>2</sup> = 66.4%	p(Effect) = 0.7506




**A-MA.1.2001.108.1: Forest Plot for Hazard Ratio of TEAEs - Pruritus (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	8 / 249	88.9	1.009 [0.378, 2.693]
GM03 – FAST	1 / 55	1 / 57	11.1	1.027 [0.064, 16.423]
<b>Total</b>	<b>11 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>1.011 [0.401, 2.551]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9906	I <sup>2</sup> = 0.0%	p(Effect) = 0.9815




**A-MA.1.2001.109.1: Forest Plot for Hazard Ratio of TEAEs - Rash (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	6 / 249	100	1.055 [0.352, 3.161]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.055 [0.352, 3.162]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9238




**A-MA.1.2001.110.1: Forest Plot for Hazard Ratio of TEAEs - Rash Maculo-Papular (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	7 / 249	100	0.657 [0.207, 2.085]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>5 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>0.657 [0.207, 2.085]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.4759




**A-MA.1.2001.111.1: Forest Plot for Hazard Ratio of TEAEs - Vascular Disorders (SOC with Incidence  $\geq 10$  Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	53 / 254	30 / 249	85.8	1.887 [1.198, 2.972]
GM03 – FAST	9 / 55	5 / 57	14.2	1.708 [0.558, 5.227]
<b>Total</b>	<b>62 / 309</b>	<b>35 / 306</b>	<b>100</b>	<b>1.861 [1.221, 2.834]</b>
Heterogeneity	Q = 0.03 (df = 1)	p = 0.8715	I <sup>2</sup> = 0.0%	p(Effect) = 0.0038



**A-MA.1.2001.111.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Vascular Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.111.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Vascular Disorders (SOC with Incidence  $\geq 10$  Patients) - Safety Analysis Set**






**A-MA.1.2001.111.4: Forest Plot for Hazard Ratio of TEAEs by Region - Vascular Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.111.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Vascular Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.112.1: Forest Plot for Hazard Ratio of TEAEs - Hypertension (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	15 / 254	7 / 249	76.9	2.070 [0.842, 5.093]
GM03 – FAST	6 / 55	2 / 57	23.1	2.666 [0.516, 13.763]
<b>Total</b>	<b>21 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>2.195 [0.997, 4.831]</b>
Heterogeneity	Q = 0.07 (df = 1)	p = 0.7911	I <sup>2</sup> = 0.0%	p(Effect) = 0.0509




**A-MA.1.2001.113.1: Forest Plot for Hazard Ratio of TEAEs - Hypotension (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	15 / 254	8 / 249	100	2.126 [0.866, 5.218]
GM03 – FAST	1 / 55	1 / 57	NC	0.001 [0.001, NC]
<b>Total</b>	<b>16 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>2.126 [0.866, 5.219]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.0997




**A-MA.1.2001.114.1: Forest Plot for Hazard Ratio of TESAEs - Blood And Lymphatic System Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	12 / 254	15 / 249	89.8	0.777 [0.362, 1.668]
GM03 – FAST	3 / 55	1 / 57	10.2	3.024 [0.314, 29.076]
<b>Total</b>	<b>15 / 309</b>	<b>16 / 306</b>	<b>100</b>	<b>0.893 [0.433, 1.841]</b>
Heterogeneity	Q = 1.24 (df = 1)	p = 0.2650	I <sup>2</sup> = 19.5%	p(Effect) = 0.7587




**A-MA.1.2001.115.1: Forest Plot for Hazard Ratio of TESAEs - Anaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.116.1: Forest Plot for Hazard Ratio of TESAEs - Gastrointestinal Disorders (SOC with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	57 / 254	53 / 249	91.5	1.074 [0.737, 1.565]
GM03 – FAST	5 / 55	5 / 57	8.5	1.025 [0.297, 3.540]
<b>Total</b>	<b>62 / 309</b>	<b>58 / 306</b>	<b>100</b>	<b>1.070 [0.746, 1.534]</b>
Heterogeneity	Q < 0.01 (df = 1)	p = 0.9437	I <sup>2</sup> = 0.0%	p(Effect) = 0.7137




**A-MA.1.2001.117.1: Forest Plot for Hazard Ratio of TESAEs - Abdominal Pain (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.118.1: Forest Plot for Hazard Ratio of TESAEs - Diarrhoea (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	10 / 249	89.1	0.682 [0.259, 1.795]
GM03 – FAST	1 / 55	1 / 57	10.9	1.011 [0.063, 16.170]
<b>Total</b>	<b>8 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>0.712 [0.285, 1.775]</b>
Heterogeneity	Q = 0.07 (df = 1)	p = 0.7928	I <sup>2</sup> = 0.0%	p(Effect) = 0.4659




**A-MA.1.2001.119.1: Forest Plot for Hazard Ratio of TESAEs - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	11 / 254	6 / 249	88.6	1.833 [0.677, 4.963]
GM03 – FAST	1 / 55	1 / 57	11.4	1.024 [0.064, 16.373]
<b>Total</b>	<b>12 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>1.715 [0.672, 4.379]</b>
Heterogeneity	Q = 0.15 (df = 1)	p = 0.6985	I <sup>2</sup> = 0.0%	p(Effect) = 0.2594




**A-MA.1.2001.120.1: Forest Plot for Hazard Ratio of TESAEs - Upper Gastrointestinal Haemorrhage (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	4 / 249	100	1.885 [0.551, 6.449]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>4 / 306</b>	<b>100</b>	<b>1.885 [0.551, 6.449]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.3124




**A-MA.1.2001.121.1: Forest Plot for Hazard Ratio of TESAEs - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	15 / 254	11 / 249	100	1.359 [0.624, 2.961]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>16 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>1.359 [0.624, 2.960]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.4400




**A-MA.1.2001.122.1: Forest Plot for Hazard Ratio of TESAEs - General Disorders And Administration Site Conditions (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	18 / 254	14 / 249	90.9	1.333 [0.652, 2.723]
GM03 – FAST	3 / 55	1 / 57	9.1	3.426 [0.356, 32.991]
<b>Total</b>	<b>21 / 309</b>	<b>15 / 306</b>	<b>100</b>	<b>1.452 [0.734, 2.871]</b>
Heterogeneity	Q = 0.61 (df = 1)	p = 0.4359	I <sup>2</sup> = 0.0%	p(Effect) = 0.2835




**A-MA.1.2001.123.1: Forest Plot for Hazard Ratio of TESAEs - Hepatobiliary Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	9 / 254	7 / 249	100	1.268 [0.465, 3.455]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>9 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>1.268 [0.465, 3.456]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.6426




**A-MA.1.2001.124.1: Forest Plot for Hazard Ratio of TESAEs - Infections And Infestations (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	26 / 254	23 / 249	100	1.108 [0.622, 1.974]
GM03 – FAST	2 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>28 / 309</b>	<b>23 / 306</b>	<b>100</b>	<b>1.108 [0.622, 1.974]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.7278




**A-MA.1.2001.125.1: Forest Plot for Hazard Ratio of TESAEs - Pneumonia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	6 / 249	100	1.311 [0.399, 4.308]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.311 [0.399, 4.308]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.6555







**A-MA.1.2001.126.1: Forest Plot for Hazard Ratio of TESAEs - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.126.2: Forest Plot for Hazard Ratio of TESAEs by Age Group 1 - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.126.3: Forest Plot for Hazard Ratio of TESAEs by Sex - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.126.4: Forest Plot for Hazard Ratio of TESAEs by Region - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.126.5: Forest Plot for Hazard Ratio of TESAEs by Number of Organs with Metastatic Sites - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.127.1: Forest Plot for Hazard Ratio of TESAEs - Investigations (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	13 / 254	10 / 249	100	1.268 [0.554, 2.902]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>13 / 309</b>	<b>10 / 306</b>	<b>100</b>	<b>1.268 [0.554, 2.902]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5741




**A-MA.1.2001.128.1: Forest Plot for Hazard Ratio of TESAEs - Platelet Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	6 / 249	100	1.335 [0.463, 3.853]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.335 [0.463, 3.851]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5930




**A-MA.1.2001.129.1: Forest Plot for Hazard Ratio of TESAEs - Metabolism And Nutrition Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	18 / 254	15 / 249	100	1.262 [0.633, 2.516]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>18 / 309</b>	<b>15 / 306</b>	<b>100</b>	<b>1.262 [0.633, 2.516]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5086






**A-MA.1.2001.130.1: Forest Plot for Hazard Ratio of TESAEs - Decreased Appetite (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.131.1: Forest Plot for Hazard Ratio of TESAEs - Hypokalaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	6 / 249	100	1.036 [0.331, 3.244]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>6 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.036 [0.331, 3.243]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9516




### A-MA.1.2001.132.1: Forest Plot for Hazard Ratio of TESAEs - Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps) (SOC with Incidence $\geq 10$ Patients) - Safety Analysis Set




**A-MA.1.2001.133.1: Forest Plot for Hazard Ratio of TESAEs - Malignant Neoplasm Progression (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	13 / 249	100	0.728 [0.306, 1.736]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>10 / 309</b>	<b>13 / 306</b>	<b>100</b>	<b>0.728 [0.306, 1.734]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.4734




**A-MA.1.2001.134.1: Forest Plot for Hazard Ratio of TESAEs - Nervous System Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	3 / 249	100	2.390 [0.618, 9.243]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>2.390 [0.618, 9.243]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2067




**A-MA.1.2001.135.1: Forest Plot for Hazard Ratio of TESAEs - Renal And Urinary Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	8 / 249	100	0.883 [0.319, 2.443]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>0.883 [0.319, 2.444]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.8106




**A-MA.1.2001.136.1: Forest Plot for Hazard Ratio of TESAEs - Respiratory, Thoracic And Mediastinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	23 / 249	100	0.431 [0.203, 0.916]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>10 / 309</b>	<b>24 / 306</b>	<b>100</b>	<b>0.431 [0.203, 0.916]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.0286




**A-MA.1.2001.136.2: Forest Plot for Hazard Ratio of TESAEs by Age Group 1 - Respiratory, Thoracic And Mediastinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**







**A-MA.1.2001.136.3: Forest Plot for Hazard Ratio of TESAEs by Sex - Respiratory, Thoracic And Mediastinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.136.4: Forest Plot for Hazard Ratio of TESAEs by Region - Respiratory, Thoracic And Mediastinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.136.5: Forest Plot for Hazard Ratio of TESAEs by Number of Organs with Metastatic Sites - Respiratory, Thoracic And Mediastinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.137.1: Forest Plot for Hazard Ratio of TESAEs - Pulmonary Embolism (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.138.1: Forest Plot for Hazard Ratio of TESAEs - Vascular Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	2 / 249	63.1	6.051 [0.727, 50.373]
GM03 – FAST	1 / 55	1 / 57	36.9	0.941 [0.059, 15.076]
<b>Total</b>	<b>7 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>3.045 [0.566, 16.397]</b>
Heterogeneity	Q = 1.09 (df = 1)	p = 0.2958	I <sup>2</sup> = 8.5%	p(Effect) = 0.1948




**A-MA.1.2001.139.1: Forest Plot for Hazard Ratio of severe TEAEs - Blood And Lymphatic System Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	51 / 254	44 / 249	71.1	1.073 [0.714, 1.612]
GM03 – FAST	25 / 55	16 / 57	28.9	1.736 [0.917, 3.287]
<b>Total</b>	<b>76 / 309</b>	<b>60 / 306</b>	<b>100</b>	<b>1.233 [0.875, 1.738]</b>
Heterogeneity	Q = 1.55 (df = 1)	p = 0.2130	I <sup>2</sup> = 35.5%	p(Effect) = 0.2314




**A-MA.1.2001.140.1: Forest Plot for Hazard Ratio of severe TEAEs - Anaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	29 / 254	28 / 249	84.4	0.920 [0.543, 1.557]
GM03 – FAST	8 / 55	6 / 57	15.6	0.751 [0.220, 2.559]
<b>Total</b>	<b>37 / 309</b>	<b>34 / 306</b>	<b>100</b>	<b>0.891 [0.549, 1.446]</b>
Heterogeneity	Q = 0.09 (df = 1)	p = 0.7657	I <sup>2</sup> = 0.0%	p(Effect) = 0.6415




**A-MA.1.2001.141.1: Forest Plot for Hazard Ratio of severe TEAEs - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	18 / 254	7 / 249	42.0	2.549 [1.062, 6.117]
GM03 – FAST	19 / 55	11 / 57	58.0	1.955 [0.928, 4.116]
<b>Total</b>	<b>37 / 309</b>	<b>18 / 306</b>	<b>100</b>	<b>2.185 [1.239, 3.854]</b>
Heterogeneity	Q = 0.20 (df = 1)	p = 0.6510	I <sup>2</sup> = 0.0%	p(Effect) = 0.0069






**A-MA.1.2001.141.2: Forest Plot for Hazard Ratio of severe TEAEs by Age Group 1 - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.141.3: Forest Plot for Hazard Ratio of severe TEAEs by Sex - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**


Subgroup Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
<b>Male</b>				
302 – GLOW	8 / 160	4 / 152	22.5	1.774 [0.533, 5.903]
GM03 – FAST	8 / 31	6 / 36	29.0	1.618 [0.561, 4.668]
<b>Total</b>	<b>16 / 191</b>	<b>10 / 188</b>	<b>51.5</b>	<b>1.684 [0.761, 3.730]</b>
Heterogeneity	Q = 0.01 (df = 1)	p = 0.9104	I <sup>2</sup> = 0.0%	p(Effect) = 0.1985
<b>Female</b>				
302 – GLOW	10 / 94	3 / 97	19.5	3.864 [1.063, 14.052]
GM03 – FAST	11 / 24	5 / 21	28.9	2.239 [0.775, 6.471]
<b>Total</b>	<b>21 / 118</b>	<b>8 / 118</b>	<b>48.5</b>	<b>2.790 [1.229, 6.333]</b>
Heterogeneity	Q = 0.41 (df = 1)	p = 0.5221	I <sup>2</sup> = 0.0%	p(Effect) = 0.0142
<b>Heterogeneity</b>	<b>Q = 0.75 (df = 1)</b>	<b>p = 0.3863</b>	<b>I<sup>2</sup> = 0.0%</b>	



**A-MA.1.2001.141.4: Forest Plot for Hazard Ratio of severe TEAEs by Region - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.141.5: Forest Plot for Hazard Ratio of severe TEAEs by Number of Organs with Metastatic Sites - Neutropenia (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.142.1: Forest Plot for Hazard Ratio of severe TEAEs - Thrombocytopenia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	7 / 249	100	1.028 [0.359, 2.938]
GM03 – FAST	0 / 55	2 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>1.028 [0.359, 2.941]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9589




**A-MA.1.2001.143.1: Forest Plot for Hazard Ratio of severe TEAEs - Gastrointestinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	75 / 254	62 / 249	85.0	1.269 [0.905, 1.778]
GM03 – FAST	12 / 55	14 / 57	15.0	0.757 [0.339, 1.690]
<b>Total</b>	<b>87 / 309</b>	<b>76 / 306</b>	<b>100</b>	<b>1.174 [0.860, 1.603]</b>
Heterogeneity	Q = 1.35 (df = 1)	p = 0.2452	I <sup>2</sup> = 26.0%	p(Effect) = 0.3118




**A-MA.1.2001.144.1: Forest Plot for Hazard Ratio of severe TEAEs - Ascites (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	8 / 249	100	0.465 [0.140, 1.549]
GM03 – FAST	0 / 55	3 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>5 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>0.465 [0.140, 1.547]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2118



**A-MA.1.2001.145.1: Forest Plot for Hazard Ratio of severe TEAEs - Diarrhoea (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	15 / 254	18 / 249	91.6	0.813 [0.409, 1.615]
GM03 – FAST	1 / 55	3 / 57	8.4	0.330 [0.034, 3.174]
<b>Total</b>	<b>16 / 309</b>	<b>21 / 306</b>	<b>100</b>	<b>0.754 [0.391, 1.454]</b>
Heterogeneity	Q = 0.56 (df = 1)	p = 0.4559	I <sup>2</sup> = 0.0%	p(Effect) = 0.3992






**A-MA.1.2001.146.1: Forest Plot for Hazard Ratio of severe TEAEs - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	22 / 254	6 / 249	73.3	3.779 [1.532, 9.323]
GM03 – FAST	4 / 55	3 / 57	26.7	1.396 [0.312, 6.238]
<b>Total</b>	<b>26 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>2.898 [1.337, 6.279]</b>
Heterogeneity	Q = 1.25 (df = 1)	p = 0.2644	I <sup>2</sup> = 19.7%	p(Effect) = 0.0070




**A-MA.1.2001.146.2: Forest Plot for Hazard Ratio of severe TEAEs by Age Group 1 - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.146.3: Forest Plot for Hazard Ratio of severe TEAEs by Sex - Nausea (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**



**A-MA.1.2001.146.4: Forest Plot for Hazard Ratio of severe TEAEs by Region - Nausea (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**




**A-MA.1.2001.146.5: Forest Plot for Hazard Ratio of severe TEAEs by Number of Organs with Metastatic Sites - Nausea (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.147.1: Forest Plot for Hazard Ratio of severe TEAEs - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	31 / 254	9 / 249	82.3	3.613 [1.720, 7.591]
GM03 – FAST	6 / 55	2 / 57	17.7	3.225 [0.650, 16.013]
<b>Total</b>	<b>37 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>3.541 [1.806, 6.945]</b>
Heterogeneity	Q = 0.02 (df = 1)	p = 0.8996	I <sup>2</sup> = 0.0%	p(Effect) = 0.0002



**A-MA.1.2001.147.2: Forest Plot for Hazard Ratio of severe TEAEs by Age Group 1 - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.147.3: Forest Plot for Hazard Ratio of severe TEAEs by Sex - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**






**A-MA.1.2001.147.4: Forest Plot for Hazard Ratio of severe TEAEs by Region - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.147.5: Forest Plot for Hazard Ratio of severe TEAEs by Number of Organs with Metastatic Sites - Vomiting (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.148.1: Forest Plot for Hazard Ratio of severe TEAEs - General Disorders And Administration Site Conditions (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	25 / 254	19 / 249	80.1	1.293 [0.711, 2.350]
GM03 – FAST	8 / 55	4 / 57	19.9	2.106 [0.634, 7.003]
<b>Total</b>	<b>33 / 309</b>	<b>23 / 306</b>	<b>100</b>	<b>1.424 [0.834, 2.433]</b>
Heterogeneity	Q = 0.51 (df = 1)	p = 0.4760	I <sup>2</sup> = 0.0%	p(Effect) = 0.1950




**A-MA.1.2001.149.1: Forest Plot for Hazard Ratio of severe TEAEs - Asthenia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	3 / 249	100	2.330 [0.602, 9.015]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>2.330 [0.602, 9.017]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2205




**A-MA.1.2001.150.1: Forest Plot for Hazard Ratio of severe TEAEs - Fatigue (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	9 / 249	74.7	0.753 [0.280, 2.024]
GM03 – FAST	4 / 55	2 / 57	25.3	2.029 [0.371, 11.097]
<b>Total</b>	<b>11 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>0.968 [0.412, 2.275]</b>
Heterogeneity	Q = 0.98 (df = 1)	p = 0.3231	I <sup>2</sup> = 0.0%	p(Effect) = 0.9400




**A-MA.1.2001.151.1: Forest Plot for Hazard Ratio of severe TEAEs - Hepatobiliary Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	9 / 254	9 / 249	100	0.967 [0.378, 2.472]
GM03 – FAST	1 / 55	1 / 57	NC	0.001 [0.001, NC]
<b>Total</b>	<b>10 / 309</b>	<b>10 / 306</b>	<b>100</b>	<b>0.967 [0.378, 2.473]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.9442




**A-MA.1.2001.152.1: Forest Plot for Hazard Ratio of severe TEAEs - Infections And Infestations (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	27 / 254	32 / 249	100	0.721 [0.423, 1.230]
GM03 – FAST	0 / 55	2 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>27 / 309</b>	<b>34 / 306</b>	<b>100</b>	<b>0.721 [0.423, 1.229]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2296



**A-MA.1.2001.153.1: Forest Plot for Hazard Ratio of severe TEAEs - Pneumonia (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	6 / 249	100	1.250 [0.419, 3.730]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.250 [0.419, 3.730]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.6891






**A-MA.1.2001.154.1: Forest Plot for Hazard Ratio of severe TEAEs - Injury, Poisoning And Procedural Complications (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	2 / 249	74.8	2.824 [0.564, 14.129]
GM03 – FAST	1 / 55	1 / 57	25.2	1.060 [0.066, 16.953]
<b>Total</b>	<b>7 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>2.206 [0.548, 8.882]</b>
Heterogeneity	Q = 0.36 (df = 1)	p = 0.5494	I <sup>2</sup> = 0.0%	p(Effect) = 0.2656




**A-MA.1.2001.155.1: Forest Plot for Hazard Ratio of severe TEAEs - Investigations (SOC with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	57 / 254	55 / 249	85.5	1.001 [0.687, 1.458]
GM03 – FAST	12 / 55	10 / 57	14.5	0.798 [0.320, 1.992]
<b>Total</b>	<b>69 / 309</b>	<b>65 / 306</b>	<b>100</b>	<b>0.969 [0.684, 1.372]</b>
Heterogeneity	Q = 0.20 (df = 1)	p = 0.6532	I <sup>2</sup> = 0.0%	p(Effect) = 0.8577




**A-MA.1.2001.156.1: Forest Plot for Hazard Ratio of severe TEAEs - Alanine Aminotransferase Increased (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	2 / 254	7 / 249	100	0.303 [0.063, 1.459]
GM03 – FAST	2 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>4 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>0.303 [0.063, 1.458]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.1364




**A-MA.1.2001.157.1: Forest Plot for Hazard Ratio of severe TEAEs - Aspartate Aminotransferase Increased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	7 / 249	100	0.783 [0.248, 2.475]
GM03 – FAST	2 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>0.783 [0.248, 2.474]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.6768




**A-MA.1.2001.158.1: Forest Plot for Hazard Ratio of severe TEAEs - Gamma-Glutamyltransferase Increased (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	4 / 254	3 / 249	53.7	1.370 [0.306, 6.135]
GM03 – FAST	4 / 55	3 / 57	46.3	0.841 [0.167, 4.226]
<b>Total</b>	<b>8 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.093 [0.364, 3.280]</b>
Heterogeneity	Q = 0.19 (df = 1)	p = 0.6643	I <sup>2</sup> = 0.0%	p(Effect) = 0.8738




**A-MA.1.2001.159.1: Forest Plot for Hazard Ratio of severe TEAEs - Neutrophil Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	26 / 254	24 / 249	100	1.066 [0.608, 1.870]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>26 / 309</b>	<b>24 / 306</b>	<b>100</b>	<b>1.066 [0.608, 1.870]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.8235




**A-MA.1.2001.160.1: Forest Plot for Hazard Ratio of severe TEAEs - Platelet Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	19 / 254	21 / 249	100	0.902 [0.484, 1.681]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>19 / 309</b>	<b>21 / 306</b>	<b>100</b>	<b>0.902 [0.484, 1.681]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.7454



**A-MA.1.2001.161.1: Forest Plot for Hazard Ratio of severe TEAEs - Weight Decreased (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	1 / 254	1 / 249	24.3	1.060 [0.066, 16.946]
GM03 – FAST	8 / 55	2 / 57	75.7	3.605 [0.747, 17.384]
<b>Total</b>	<b>9 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>2.676 [0.681, 10.518]</b>
Heterogeneity	Q = 0.57 (df = 1)	p = 0.4519	I <sup>2</sup> = 0.0%	p(Effect) = 0.1587






**A-MA.1.2001.162.1: Forest Plot for Hazard Ratio of severe TEAEs - White Blood Cell Count Decreased (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	5 / 254	10 / 249	100	0.518 [0.177, 1.521]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>5 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>0.518 [0.177, 1.518]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2306




**A-MA.1.2001.163.1: Forest Plot for Hazard Ratio of severe TEAEs - Metabolism And Nutrition Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	41 / 254	33 / 249	96.5	1.285 [0.811, 2.037]
GM03 – FAST	2 / 55	2 / 57	3.5	0.499 [0.045, 5.509]
<b>Total</b>	<b>43 / 309</b>	<b>35 / 306</b>	<b>100</b>	<b>1.243 [0.791, 1.953]</b>
Heterogeneity	Q = 0.57 (df = 1)	p = 0.4487	I <sup>2</sup> = 0.0%	p(Effect) = 0.3464




**A-MA.1.2001.164.1: Forest Plot for Hazard Ratio of severe TEAEs - Decreased Appetite (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	17 / 254	4 / 249	100	4.606 [1.548, 13.709]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>17 / 309</b>	<b>4 / 306</b>	<b>100</b>	<b>4.606 [1.548, 13.707]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.0061




**A-MA.1.2001.164.2: Forest Plot for Hazard Ratio of severe TEAEs by Age Group 1 - Decreased Appetite (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.164.3: Forest Plot for Hazard Ratio of severe TEAEs by Sex - Decreased Appetite (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.164.4: Forest Plot for Hazard Ratio of severe TEAEs by Region - Decreased Appetite (PT with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.164.5: Forest Plot for Hazard Ratio of severe TEAEs by Number of Organs with Metastatic Sites - Decreased Appetite (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.165.1: Forest Plot for Hazard Ratio of severe TEAEs - Hypoalbuminaemia (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	4 / 249	100	2.039 [0.613, 6.784]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>5 / 306</b>	<b>100</b>	<b>2.039 [0.613, 6.783]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2453






**A-MA.1.2001.166.1: Forest Plot for Hazard Ratio of severe TEAEs - Hypokalaemia (PT with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	14 / 254	17 / 249	100	0.776 [0.380, 1.587]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>14 / 309</b>	<b>17 / 306</b>	<b>100</b>	<b>0.776 [0.380, 1.586]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.4868




**A-MA.1.2001.167.1: Forest Plot for Hazard Ratio of severe TEAEs - Hyponatraemia (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	4 / 254	9 / 249	100	0.469 [0.144, 1.524]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>4 / 309</b>	<b>10 / 306</b>	<b>100</b>	<b>0.469 [0.144, 1.526]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2084




**A-MA.1.2001.168.1: Forest Plot for Hazard Ratio of severe TEAEs - Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps) (SOC with Incidence >=10 Patients) - Safety Analysis Set**




**A-MA.1.2001.169.1: Forest Plot for Hazard Ratio of severe TEAEs - Malignant Neoplasm Progression (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	13 / 249	100	0.728 [0.306, 1.736]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>10 / 309</b>	<b>13 / 306</b>	<b>100</b>	<b>0.728 [0.306, 1.734]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.4734




**A-MA.1.2001.170.1: Forest Plot for Hazard Ratio of severe TEAEs - Nervous System Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	11 / 254	14 / 249	89.2	0.785 [0.356, 1.731]
GM03 – FAST	1 / 55	3 / 57	10.8	0.350 [0.036, 3.369]
<b>Total</b>	<b>12 / 309</b>	<b>17 / 306</b>	<b>100</b>	<b>0.719 [0.341, 1.518]</b>
Heterogeneity	Q = 0.43 (df = 1)	p = 0.5101	I <sup>2</sup> = 0.0%	p(Effect) = 0.3871




**A-MA.1.2001.171.1: Forest Plot for Hazard Ratio of severe TEAEs - Renal And Urinary Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	8 / 254	6 / 249	100	1.372 [0.475, 3.965]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>7 / 306</b>	<b>100</b>	<b>1.372 [0.475, 3.964]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.5591




**A-MA.1.2001.172.1: Forest Plot for Hazard Ratio of severe TEAEs - Respiratory, Thoracic And Mediastinal Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.173.1: Forest Plot for Hazard Ratio of severe TEAEs - Pulmonary Embolism (PT with Incidence >=10 Patients) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	4 / 254	9 / 249	100	0.421 [0.129, 1.373]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>4 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>0.421 [0.129, 1.373]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.1516






**A-MA.1.2001.174.1: Forest Plot for Hazard Ratio of severe TEAEs - Skin And Subcutaneous Tissue Disorders (SOC with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	9 / 254	10 / 249	100	0.842 [0.338, 2.093]
GM03 – FAST	0 / 55	1 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>9 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>0.842 [0.338, 2.095]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.7116




**A-MA.1.2001.175.1: Forest Plot for Hazard Ratio of severe TEAEs - Palmar-Plantar Erythrodyssaes-  
thesia Syndrome (PT with Incidence >=10 Patients) - Safety Analysis Set**



**A-MA.1.2001.176.1: Forest Plot for Hazard Ratio of severe TEAEs - Vascular Disorders (SOC with Incidence  $\geq 10$  Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	12 / 254	5 / 249	84.0	2.290 [0.804, 6.528]
GM03 – FAST	2 / 55	1 / 57	16.0	1.970 [0.178, 21.750]
<b>Total</b>	<b>14 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>2.236 [0.856, 5.838]</b>
Heterogeneity	Q = 0.01 (df = 1)	p = 0.9104	I <sup>2</sup> = 0.0%	p(Effect) = 0.1005



**A-MA.1.2001.177.1: Forest Plot for Hazard Ratio of severe TEAEs - Hypertension (PT with Incidence >=10 Patients) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	3 / 249	100	1.834 [0.455, 7.400]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>1.834 [0.455, 7.396]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.3940




Table A-2MA.1.2000.5: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event - Safety Analysis Set

MedDRA SOC and PT	Zolbetuximab (N=309)	Placebo (N=306)	Total (N=615)
Overall	92 ( 29.8%)	75 ( 24.5%)	167 ( 27.2%)
Blood And Lymphatic System Disorders	8 ( 2.6%)	10 ( 3.3%)	18 ( 2.9%)
Anaemia	1 ( 0.3%)	3 ( 1.0%)	4 ( 0.7%)
Coagulopathy	0	1 ( 0.3%)	1 ( 0.2%)
Disseminated Intravascular Coagulation	1 ( 0.3%)	0	1 ( 0.2%)
Leukopenia	0	1 ( 0.3%)	1 ( 0.2%)
Neutropenia	5 ( 1.6%)	6 ( 2.0%)	11 ( 1.8%)
Thrombocytopenia	3 ( 1.0%)	0	3 ( 0.5%)
Cardiac Disorders	2 ( 0.6%)	2 ( 0.7%)	4 ( 0.7%)
Atrial Fibrillation	1 ( 0.3%)	0	1 ( 0.2%)
Cardiac Arrest	0	1 ( 0.3%)	1 ( 0.2%)
Cardio-Respiratory Arrest	1 ( 0.3%)	1 ( 0.3%)	2 ( 0.3%)
Congenital, Familial And Genetic Disorders	1 ( 0.3%)	0	1 ( 0.2%)
Gene Mutation	1 ( 0.3%)	0	1 ( 0.2%)
Gastrointestinal Disorders	29 ( 9.4%)	20 ( 6.5%)	49 ( 8.0%)
Abdominal Pain	4 ( 1.3%)	0	4 ( 0.7%)
Abdominal Pain Upper	1 ( 0.3%)	1 ( 0.3%)	2 ( 0.3%)
Diarrhoea	5 ( 1.6%)	3 ( 1.0%)	8 ( 1.3%)
Dysphagia	2 ( 0.6%)	0	2 ( 0.3%)
Enterocolitis	0	1 ( 0.3%)	1 ( 0.2%)
Gastric Haemorrhage	0	3 ( 1.0%)	3 ( 0.5%)
Gastric Stenosis	1 ( 0.3%)	0	1 ( 0.2%)
Gastroesophageal Reflux Disease	0	1 ( 0.3%)	1 ( 0.2%)
Haematemesis	0	1 ( 0.3%)	1 ( 0.2%)
Haemorrhagic Ascites	1 ( 0.3%)	0	1 ( 0.2%)
Ileus	1 ( 0.3%)	1 ( 0.3%)	2 ( 0.3%)
Intestinal Fistula	0	1 ( 0.3%)	1 ( 0.2%)

Abbreviations: N=number of patients; PT=preferred term; SOC=system organ class.  
Sorting order: system organ class and preferred terms are sorted alphabetically.  
ASTELLAS final Data Cuts

Table A-2MA.1.2000.5: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event - Safety Analysis Set

MedDRA SOC and PT	Zolbetuximab (N=309)	Placebo (N=306)	Total (N=615)
Intestinal Obstruction	1 ( 0.3%)	0	1 ( 0.2%)
Intra-Abdominal Haemorrhage	0	1 ( 0.3%)	1 ( 0.2%)
Nausea	7 ( 2.3%)	3 ( 1.0%)	10 ( 1.6%)
Obstruction Gastric	2 ( 0.6%)	1 ( 0.3%)	3 ( 0.5%)
Swollen Tongue	1 ( 0.3%)	0	1 ( 0.2%)
Upper Gastrointestinal Haemorrhage	3 ( 1.0%)	1 ( 0.3%)	4 ( 0.7%)
Vomiting	11 ( 3.6%)	6 ( 2.0%)	17 ( 2.8%)
General Disorders And Administration Site Conditions	13 ( 4.2%)	7 ( 2.3%)	20 ( 3.3%)
Asthenia	3 ( 1.0%)	2 ( 0.7%)	5 ( 0.8%)
Chest Discomfort	2 ( 0.6%)	1 ( 0.3%)	3 ( 0.5%)
Death	2 ( 0.6%)	1 ( 0.3%)	3 ( 0.5%)
Fatigue	2 ( 0.6%)	0	2 ( 0.3%)
General Physical Health Deterioration	0	1 ( 0.3%)	1 ( 0.2%)
Malaise	2 ( 0.6%)	0	2 ( 0.3%)
Mucosal Inflammation	0	1 ( 0.3%)	1 ( 0.2%)
Multi-Organ Failure	1 ( 0.3%)	0	1 ( 0.2%)
Performance Status Decreased	0	1 ( 0.3%)	1 ( 0.2%)
Sudden Death	1 ( 0.3%)	0	1 ( 0.2%)
Hepatobiliary Disorders	3 ( 1.0%)	5 ( 1.6%)	8 ( 1.3%)
Deficiency Of Bile Secretion	1 ( 0.3%)	0	1 ( 0.2%)
Hepatic Failure	1 ( 0.3%)	0	1 ( 0.2%)
Hepatic Function Abnormal	1 ( 0.3%)	0	1 ( 0.2%)
Hepatitis Acute	0	1 ( 0.3%)	1 ( 0.2%)
Hepatotoxicity	0	1 ( 0.3%)	1 ( 0.2%)
Hyperbilirubinaemia	0	2 ( 0.7%)	2 ( 0.3%)
Jaundice	1 ( 0.3%)	0	1 ( 0.2%)
Jaundice Cholestatic	0	1 ( 0.3%)	1 ( 0.2%)

Abbreviations: N=number of patients; PT=preferred term; SOC=system organ class.

Sorting order: system organ class and preferred terms are sorted alphabetically.

ASTELLAS final Data Cuts

Table A-2MA.1.2000.5: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event - Safety Analysis Set

MedDRA SOC and PT	Zolbetuximab (N=309)	Placebo (N=306)	Total (N=615)
Immune System Disorders	3 ( 1.0%)	1 ( 0.3%)	4 ( 0.7%)
Anaphylactic Reaction	3 ( 1.0%)	1 ( 0.3%)	4 ( 0.7%)
Infections And Infestations	6 ( 1.9%)	8 ( 2.6%)	14 ( 2.3%)
Abdominal Infection	1 ( 0.3%)	1 ( 0.3%)	2 ( 0.3%)
Escherichia Infection	0	1 ( 0.3%)	1 ( 0.2%)
Infection	0	1 ( 0.3%)	1 ( 0.2%)
Lower Respiratory Tract Infection	1 ( 0.3%)	0	1 ( 0.2%)
Mucosal Infection	0	1 ( 0.3%)	1 ( 0.2%)
Peritonitis	0	1 ( 0.3%)	1 ( 0.2%)
Pneumonia	3 ( 1.0%)	2 ( 0.7%)	5 ( 0.8%)
Septic Shock	1 ( 0.3%)	2 ( 0.7%)	3 ( 0.5%)
Injury, Poisoning And Procedural Complications	4 ( 1.3%)	0	4 ( 0.7%)
Fall	1 ( 0.3%)	0	1 ( 0.2%)
Head Injury	1 ( 0.3%)	0	1 ( 0.2%)
Infusion Related Reaction	2 ( 0.6%)	0	2 ( 0.3%)
Procedural Complication	1 ( 0.3%)	0	1 ( 0.2%)
Investigations	18 ( 5.8%)	8 ( 2.6%)	26 ( 4.2%)
Alanine Aminotransferase Increased	4 ( 1.3%)	1 ( 0.3%)	5 ( 0.8%)
Aspartate Aminotransferase Increased	3 ( 1.0%)	2 ( 0.7%)	5 ( 0.8%)
Blood Alkaline Phosphatase Increased	1 ( 0.3%)	0	1 ( 0.2%)
Blood Bilirubin Increased	4 ( 1.3%)	0	4 ( 0.7%)
Blood Pressure Decreased	1 ( 0.3%)	0	1 ( 0.2%)
Ejection Fraction Decreased	1 ( 0.3%)	1 ( 0.3%)	2 ( 0.3%)
Gamma-Glutamyltransferase Increased	2 ( 0.6%)	0	2 ( 0.3%)
Neutrophil Count Decreased	3 ( 1.0%)	2 ( 0.7%)	5 ( 0.8%)
Platelet Count Decreased	5 ( 1.6%)	3 ( 1.0%)	8 ( 1.3%)
Weight Decreased	3 ( 1.0%)	0	3 ( 0.5%)

Abbreviations: N=number of patients; PT=preferred term; SOC=system organ class.

Sorting order: system organ class and preferred terms are sorted alphabetically.

ASTELLAS final Data Cuts

Table A-2MA.1.2000.5: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event - Safety Analysis Set

MedDRA SOC and PT	Zolbetuximab (N=309)	Placebo (N=306)	Total (N=615)
White Blood Cell Count Decreased	0	1 ( 0.3%)	1 ( 0.2%)
Metabolism And Nutrition Disorders	5 ( 1.6%)	6 ( 2.0%)	11 ( 1.8%)
Acidosis	0	1 ( 0.3%)	1 ( 0.2%)
Decreased Appetite	2 ( 0.6%)	3 ( 1.0%)	5 ( 0.8%)
Dehydration	1 ( 0.3%)	0	1 ( 0.2%)
Electrolyte Imbalance	0	1 ( 0.3%)	1 ( 0.2%)
Hypoalbuminaemia	0	1 ( 0.3%)	1 ( 0.2%)
Hypokalaemia	1 ( 0.3%)	0	1 ( 0.2%)
Hypophosphataemia	1 ( 0.3%)	0	1 ( 0.2%)
Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)	5 ( 1.6%)	7 ( 2.3%)	12 ( 2.0%)
Malignant Neoplasm Progression	4 ( 1.3%)	4 ( 1.3%)	8 ( 1.3%)
Metastases To Meninges	0	1 ( 0.3%)	1 ( 0.2%)
Metastases To Peritoneum	0	1 ( 0.3%)	1 ( 0.2%)
Neoplasm Malignant	1 ( 0.3%)	0	1 ( 0.2%)
Tumour Haemorrhage	0	1 ( 0.3%)	1 ( 0.2%)
Nervous System Disorders	16 ( 5.2%)	10 ( 3.3%)	26 ( 4.2%)
Cerebral Haemorrhage	1 ( 0.3%)	0	1 ( 0.2%)
Cerebrovascular Accident	2 ( 0.6%)	0	2 ( 0.3%)
Dizziness	1 ( 0.3%)	1 ( 0.3%)	2 ( 0.3%)
Dysaesthesia	1 ( 0.3%)	0	1 ( 0.2%)
Dysarthria	0	1 ( 0.3%)	1 ( 0.2%)
Epilepsy	0	1 ( 0.3%)	1 ( 0.2%)
Hypoaesthesia	2 ( 0.6%)	0	2 ( 0.3%)
Intracranial Pressure Increased	1 ( 0.3%)	0	1 ( 0.2%)
Neuropathy Peripheral	1 ( 0.3%)	2 ( 0.7%)	3 ( 0.5%)
Neurotoxicity	0	1 ( 0.3%)	1 ( 0.2%)
Paraesthesia	2 ( 0.6%)	0	2 ( 0.3%)

Abbreviations: N=number of patients; PT=preferred term; SOC=system organ class.


Sorting order: system organ class and preferred terms are sorted alphabetically.

ASTELLAS final Data Cuts




**A-MA.1.2001.180.1: Forest Plot for Hazard Ratio of TEAEs - Hypersensitivity Reactions (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	39 / 254	27 / 249	82.1	1.422 [0.868, 2.330]
GM03 – FAST	7 / 55	8 / 57	17.9	0.784 [0.272, 2.262]
<b>Total</b>	<b>46 / 309</b>	<b>35 / 306</b>	<b>100</b>	<b>1.279 [0.817, 2.000]</b>
Heterogeneity	Q = 1.00 (df = 1)	p = 0.3179	I <sup>2</sup> = 0.0%	p(Effect) = 0.2817




**A-MA.1.2001.180.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Hypersensitivity Reactions (AESI) - Safety Analysis Set**



**A-MA.1.2001.180.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.180.4: Forest Plot for Hazard Ratio of TEAEs by Region - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.180.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Hypersensitivity Reactions (AESI) - Safety Analysis Set**

Subgroup Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
<b>0-2</b>				
302 – GLOW	29 / 190	20 / 186	61.0	1.380 [0.779, 2.444]
GM03 – FAST	1 / 17	2 / 17	3.4	0.512 [0.046, 5.654]
<b>Total</b>	<b>30 / 207</b>	<b>22 / 203</b>	<b>64.5</b>	<b>1.309 [0.750, 2.283]</b>
Heterogeneity	Q = 0.62 (df = 1)	p = 0.4319	I <sup>2</sup> = 0.0%	p(Effect) = 0.3430
<b>&gt;=3</b>				
302 – GLOW	10 / 64	7 / 63	21.4	1.446 [0.550, 3.801]
GM03 – FAST	6 / 38	6 / 40	14.2	0.904 [0.276, 2.964]
<b>Total</b>	<b>16 / 102</b>	<b>13 / 103</b>	<b>35.5</b>	<b>1.199 [0.567, 2.537]</b>
Heterogeneity	Q = 0.36 (df = 1)	p = 0.5475	I <sup>2</sup> = 0.0%	p(Effect) = 0.6350
<b>Heterogeneity</b>	<b>Q = 0.03 (df = 1)</b>	<b>p = 0.8541</b>	<b>I<sup>2</sup> = 0.0%</b>	




**A-MA.1.2001.181.1: Forest Plot for Hazard Ratio of TEAEs - Infusion Related Reaction (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	91 / 254	25 / 249	57.8	4.541 [2.908, 7.092]
GM03 – FAST	31 / 55	27 / 57	42.2	1.256 [0.745, 2.116]
<b>Total</b>	<b>122 / 309</b>	<b>52 / 306</b>	<b>100</b>	<b>2.641 [1.882, 3.706]</b>
Heterogeneity	Q = 13.47 (df = 1)	p = 0.0002	I <sup>2</sup> = 92.6%	p(Effect) < 0.0001



**A-MA.1.2001.181.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Infusion Related Reaction (AESI) - Safety Analysis Set**




### A-MA.1.2001.181.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Infusion Related Reaction (AESI) - Safety Analysis Set






**A-MA.1.2001.181.4: Forest Plot for Hazard Ratio of TEAEs by Region - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.181.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.182.1: Forest Plot for Hazard Ratio of TEAEs - Nausea (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	175 / 254	125 / 249	76.3	1.961 [1.554, 2.477]
GM03 – FAST	46 / 55	44 / 57	23.7	1.364 [0.898, 2.074]
<b>Total</b>	<b>221 / 309</b>	<b>169 / 306</b>	<b>100</b>	<b>1.799 [1.468, 2.206]</b>
Heterogeneity	Q = 2.21 (df = 1)	p = 0.1375	I <sup>2</sup> = 54.7%	p(Effect) < 0.0001




**A-MA.1.2001.182.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.182.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Nausea (AESI) - Safety Analysis Set**



**A-MA.1.2001.182.4: Forest Plot for Hazard Ratio of TEAEs by Region - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.182.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.184.1: Forest Plot for Hazard Ratio of TEAEs - Vomiting (AESI) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	169 / 254	79 / 249	74.4	3.345 [2.552, 4.383]
GM03 – FAST	42 / 55	34 / 57	25.6	1.861 [1.173, 2.952]
<b>Total</b>	<b>211 / 309</b>	<b>113 / 306</b>	<b>100</b>	<b>2.879 [2.280, 3.636]</b>
Heterogeneity	Q = 4.62 (df = 1)	p = 0.0317	I <sup>2</sup> = 78.3%	p(Effect) < 0.0001







### A-MA.1.2001.184.2: Forest Plot for Hazard Ratio of TEAEs by Age Group 1 - Vomiting (AESI) - Safety Analysis Set




**A-MA.1.2001.184.3: Forest Plot for Hazard Ratio of TEAEs by Sex - Vomiting (AESI) - Safety Analysis Set**



**A-MA.1.2001.184.4: Forest Plot for Hazard Ratio of TEAEs by Region - Vomiting (AESI) - Safety Analysis Set**




### A-MA.1.2001.184.5: Forest Plot for Hazard Ratio of TEAEs by Number of Organs with Metastatic Sites - Vomiting (AESI) - Safety Analysis Set




**A-MA.1.2001.187.1: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) - Hypersensitivity Reactions (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	34 / 254	25 / 249	80.6	1.354 [0.806, 2.275]
GM03 – FAST	7 / 55	8 / 57	19.4	0.784 [0.272, 2.262]
<b>Total</b>	<b>41 / 309</b>	<b>33 / 306</b>	<b>100</b>	<b>1.218 [0.764, 1.941]</b>
Heterogeneity	Q = 0.82 (df = 1)	p = 0.3638	I <sup>2</sup> = 0.0%	p(Effect) = 0.4065




**A-MA.1.2001.187.2: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Age Group 1 - Hypersensitivity Reactions (AESI) - Safety Analysis Set**



**A-MA.1.2001.187.3: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Sex - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.187.4: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Region - Hypersensitivity Reactions (AESI) - Safety Analysis Set**






**A-MA.1.2001.187.5: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Number of Organs with Metastatic Sites - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.188.1: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) - Infusion Related Reaction (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	84 / 254	24 / 249	56.7	4.269 [2.704, 6.738]
GM03 – FAST	31 / 55	27 / 57	43.3	1.249 [0.741, 2.105]
<b>Total</b>	<b>115 / 309</b>	<b>51 / 306</b>	<b>100</b>	<b>2.506 [1.777, 3.534]</b>
Heterogeneity	Q = 12.07 (df = 1)	p = 0.0005	I <sup>2</sup> = 91.7%	p(Effect) < 0.0001




**A-MA.1.2001.188.2: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Age Group 1 - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.188.3: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Sex - Infusion Related Reaction (AESI) - Safety Analysis Set**



**A-MA.1.2001.188.4: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Region - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.188.5: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Number of Organs with Metastatic Sites - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.189.1: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) - Nausea (AESI) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	168 / 254	123 / 249	76.0	1.861 [1.470, 2.357]
GM03 – FAST	45 / 55	44 / 57	24.0	1.284 [0.844, 1.955]
<b>Total</b>	<b>213 / 309</b>	<b>167 / 306</b>	<b>100</b>	<b>1.702 [1.386, 2.091]</b>
Heterogeneity	Q = 2.28 (df = 1)	p = 0.1311	I <sup>2</sup> = 56.1%	p(Effect) < 0.0001




**A-MA.1.2001.189.2: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Age Group 1 - Nausea (AESI) - Safety Analysis Set**






**A-MA.1.2001.189.3: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Sex - Nausea (AESI) - Safety Analysis Set**



**A-MA.1.2001.189.4: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Region - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.189.5: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Number of Organs with Metastatic Sites - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.191.1: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) - Vomiting (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	161 / 254	75 / 249	73.6	3.204 [2.429, 4.226]
GM03 – FAST	41 / 55	34 / 57	26.4	1.763 [1.110, 2.800]
<b>Total</b>	<b>202 / 309</b>	<b>109 / 306</b>	<b>100</b>	<b>2.737 [2.158, 3.471]</b>
Heterogeneity	Q = 4.72 (df = 1)	p = 0.0299	I <sup>2</sup> = 78.8%	p(Effect) < 0.0001




**A-MA.1.2001.191.2: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Age Group 1 - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.191.3: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Sex - Vomiting (AESI) - Safety Analysis Set**



**A-MA.1.2001.191.4: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Region - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.191.5: Forest Plot for Hazard Ratio of Non-Severe TEAEs (CTCAE Grade <3) by Number of Organs with Metastatic Sites - Vomiting (AESI) - Safety Analysis Set**






### A-MA.1.2001.194.1: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade $\geq 3$ ) - Hypersensitivity Reactions (AESI) - Safety Analysis Set


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	4 / 249	100	1.580 [0.456, 5.472]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>4 / 306</b>	<b>100</b>	<b>1.580 [0.456, 5.473]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.4705




**A-MA.1.2001.194.2: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Age Group 1 - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.194.3: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Sex - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.194.4: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Region - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.194.5: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Number of Organs with Metastatic Sites - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




### A-MA.1.2001.195.1: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade $\geq 3$ ) - Infusion Related Reaction (AESI) - Safety Analysis Set



**A-MA.1.2001.195.2: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Age Group 1 - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.195.3: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Sex - Infusion Related Reaction (AESI) - Safety Analysis Set**






**A-MA.1.2001.195.4: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Region - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.195.5: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Number of Organs with Metastatic Sites - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.196.1: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) - Nausea (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	22 / 254	6 / 249	73.3	3.779 [1.532, 9.323]
GM03 – FAST	4 / 55	3 / 57	26.7	1.396 [0.312, 6.238]
<b>Total</b>	<b>26 / 309</b>	<b>9 / 306</b>	<b>100</b>	<b>2.898 [1.337, 6.279]</b>
Heterogeneity	Q = 1.25 (df = 1)	p = 0.2644	I <sup>2</sup> = 19.7%	p(Effect) = 0.0070




**A-MA.1.2001.196.2: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Age Group 1 - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.196.3: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Sex - Nausea (AESI) - Safety Analysis Set**



**A-MA.1.2001.196.4: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Region - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.196.5: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Number of Organs with Metastatic Sites - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.198.1: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade >=3) - Vomiting (AESI) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	31 / 254	9 / 249	82.3	3.613 [1.720, 7.591]
GM03 – FAST	6 / 55	2 / 57	17.7	3.225 [0.650, 16.013]
<b>Total</b>	<b>37 / 309</b>	<b>11 / 306</b>	<b>100</b>	<b>3.541 [1.806, 6.945]</b>
Heterogeneity	Q = 0.02 (df = 1)	p = 0.8996	I <sup>2</sup> = 0.0%	p(Effect) = 0.0002







**A-MA.1.2001.198.2: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Age Group 1 - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.198.3: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Sex - Vomiting (AESI) - Safety Analysis Set**



**A-MA.1.2001.198.4: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Region - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.198.5: Forest Plot for Hazard Ratio of Severe TEAEs (CTCAE Grade  $\geq 3$ ) by Number of Organs with Metastatic Sites - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.201.1: Forest Plot for Hazard Ratio of TESAEs - Hypersensitivity Reactions (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	3 / 249	100	2.394 [0.618, 9.266]
GM03 – FAST	0 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>2.394 [0.618, 9.270]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.2063




**A-MA.1.2001.201.2: Forest Plot for Hazard Ratio of TESAEs by Age Group 1 - Hypersensitivity Reactions (AESI) - Safety Analysis Set**



**A-MA.1.2001.201.3: Forest Plot for Hazard Ratio of TESAEs by Sex - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.201.4: Forest Plot for Hazard Ratio of TESAEs by Region - Hypersensitivity Reactions (AESI) - Safety Analysis Set**







**A-MA.1.2001.201.5: Forest Plot for Hazard Ratio of TESAEs by Number of Organs with Metastatic Sites - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.202.1: Forest Plot for Hazard Ratio of TESAEs - Infusion Related Reaction (AESI) - Safety Analysis Set**




### A-MA.1.2001.202.2: Forest Plot for Hazard Ratio of TESAEs by Age Group 1 - Infusion Related Reaction (AESI) - Safety Analysis Set




**A-MA.1.2001.202.3: Forest Plot for Hazard Ratio of TESAEs by Sex - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.202.4: Forest Plot for Hazard Ratio of TESAEs by Region - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.202.5: Forest Plot for Hazard Ratio of TESAEs by Number of Organs with Metastatic Sites - Infusion Related Reaction (AESI) - Safety Analysis Set**



**A-MA.1.2001.203.1: Forest Plot for Hazard Ratio of TESAEs - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.203.2: Forest Plot for Hazard Ratio of TESAEs by Age Group 1 - Nausea (AESI) - Safety Analysis Set**







**A-MA.1.2001.203.3: Forest Plot for Hazard Ratio of TESAEs by Sex - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.203.4: Forest Plot for Hazard Ratio of TESAEs by Region - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.203.5: Forest Plot for Hazard Ratio of TESAEs by Number of Organs with Metastatic Sites - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.205.1: Forest Plot for Hazard Ratio of TESAEs - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.205.2: Forest Plot for Hazard Ratio of TESAEs by Age Group 1 - Vomiting (AESI) - Safety Analysis Set**




### A-MA.1.2001.205.3: Forest Plot for Hazard Ratio of TESAEs by Sex - Vomiting (AESI) - Safety Analysis Set



**A-MA.1.2001.205.4: Forest Plot for Hazard Ratio of TESAEs by Region - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.205.5: Forest Plot for Hazard Ratio of TESAEs by Number of Organs with Metastatic Sites - Vomiting (AESI) - Safety Analysis Set**






**A-MA.1.2001.208.1: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation - Hypersensitivity Reactions (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	7 / 254	1 / 249	100	6.978 [0.858, 56.754]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>8 / 309</b>	<b>1 / 306</b>	<b>100</b>	<b>6.978 [0.858, 56.753]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.0693




**A-MA.1.2001.208.2: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Age Group 1 - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.208.3: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Sex - Hypersensitivity Reactions (AESI) - Safety Analysis Set**



**A-MA.1.2001.208.4: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Region - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.208.5: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Number of Organs with Metastatic Sites - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.209.1: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation - Infusion Related Reaction (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	10 / 254	1 / 249	100	9.604 [1.229, 75.046]
GM03 – FAST	2 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>12 / 309</b>	<b>1 / 306</b>	<b>100</b>	<b>9.604 [1.229, 75.048]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.0310



**A-MA.1.2001.209.2: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Age Group 1 - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.209.3: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Sex - Infusion Related Reaction (AESI) - Safety Analysis Set**






**A-MA.1.2001.209.4: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Region - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.209.5: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Number of Organs with Metastatic Sites - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.210.1: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation - Nausea (AESI) - Safety Analysis Set**


Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	6 / 254	3 / 249	100	1.900 [0.475, 7.604]
GM03 – FAST	1 / 55	0 / 57	NC	NC [NC, NC]
<b>Total</b>	<b>7 / 309</b>	<b>3 / 306</b>	<b>100</b>	<b>1.900 [0.475, 7.602]</b>
Heterogeneity	Q = NC	p = NC	I <sup>2</sup> = NC	p(Effect) = 0.3643




**A-MA.1.2001.210.2: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Age Group 1 - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.210.3: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Sex - Nausea (AESI) - Safety Analysis Set**



**A-MA.1.2001.210.4: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Region - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.210.5: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Number of Organs with Metastatic Sites - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.212.1: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation - Vomiting (AESI) - Safety Analysis Set**

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
302 – GLOW	9 / 254	4 / 249	73.5	2.181 [0.671, 7.087]
GM03 – FAST	2 / 55	2 / 57	26.5	1.007 [0.141, 7.171]
<b>Total</b>	<b>11 / 309</b>	<b>6 / 306</b>	<b>100</b>	<b>1.778 [0.647, 4.884]</b>
Heterogeneity	Q = 0.44 (df = 1)	p = 0.5085	I <sup>2</sup> = 0.0%	p(Effect) = 0.2646







**A-MA.1.2001.212.2: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Age Group 1 - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.212.3: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Sex - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.212.4: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Region - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.212.5: Forest Plot for Hazard Ratio of TEAEs leading to permanent treatment discontinuation by Number of Organs with Metastatic Sites - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.236.1: Forest Plot for Hazard Ratio of TEAEs leading to death - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.236.2: Forest Plot for Hazard Ratio of TEAEs leading to death by Age Group 1 - Hypersensitivity Reactions (AESI) - Safety Analysis Set**



**A-MA.1.2001.236.3: Forest Plot for Hazard Ratio of TEAEs leading to death by Sex - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.236.4: Forest Plot for Hazard Ratio of TEAEs leading to death by Region - Hypersensitivity Reactions (AESI) - Safety Analysis Set**







**A-MA.1.2001.236.5: Forest Plot for Hazard Ratio of TEAEs leading to death by Number of Organs with Metastatic Sites - Hypersensitivity Reactions (AESI) - Safety Analysis Set**




**A-MA.1.2001.237.1: Forest Plot for Hazard Ratio of TEAEs leading to death - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.237.2: Forest Plot for Hazard Ratio of TEAEs leading to death by Age Group 1 - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.237.3: Forest Plot for Hazard Ratio of TEAEs leading to death by Sex - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.237.4: Forest Plot for Hazard Ratio of TEAEs leading to death by Region - Infusion Related Reaction (AESI) - Safety Analysis Set**




**A-MA.1.2001.237.5: Forest Plot for Hazard Ratio of TEAEs leading to death by Number of Organs with Metastatic Sites - Infusion Related Reaction (AESI) - Safety Analysis Set**



**A-MA.1.2001.238.1: Forest Plot for Hazard Ratio of TEAEs leading to death - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.238.2: Forest Plot for Hazard Ratio of TEAEs leading to death by Age Group 1 - Nausea (AESI) - Safety Analysis Set**







**A-MA.1.2001.238.3: Forest Plot for Hazard Ratio of TEAEs leading to death by Sex - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.238.4: Forest Plot for Hazard Ratio of TEAEs leading to death by Region - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.238.5: Forest Plot for Hazard Ratio of TEAEs leading to death by Number of Organs with Metastatic Sites - Nausea (AESI) - Safety Analysis Set**




**A-MA.1.2001.240.1: Forest Plot for Hazard Ratio of TEAEs leading to death - Vomiting (AESI) - Safety Analysis Set**




**A-MA.1.2001.240.2: Forest Plot for Hazard Ratio of TEAEs leading to death by Age Group 1 - Vomiting (AESI) - Safety Analysis Set**



**A-MA.1.2001.240.3: Forest Plot for Hazard Ratio of TEAEs leading to death by Sex - Vomiting (AESI) - Safety Analysis Set**



**A-MA.1.2001.240.4: Forest Plot for Hazard Ratio of TEAEs leading to death by Region - Vomiting (AESI) - Safety Analysis Set**



**A-MA.1.2001.240.5: Forest Plot for Hazard Ratio of TEAEs leading to death by Number of Organs with Metastatic Sites - Vomiting (AESI) - Safety Analysis Set**

